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Background: The generation of patient-customized cell sources for refining cellular 
replacement therapy is a significant technical challenge. Allogeneic mesenchymal 
stromal cells (MSC), maintained and expanded in vitro, represent an excellent cellular 
source for immune therapy and regenerative medicine. However, the potential for 
immune mediated rejection of these cells post-transplantation remains controversial. 
Due to the large numbers of cells required for successful implantation, there is a 
requirement for the ex vivo expansion of MSC which are derived in relatively small 
numbers from umbilical cord blood or bone marrow. There is growing literature 
suggesting that the biology and genetics of MSC change in extended culture and these 
have the potential to impact on the immunological status of the cells. This makes a 
detailed and comprehensive study of the immunobiology of cultured MSC an 
imperative for predicting future therapeutic efficacy. This was the principle goal of 
this project. 
 
Hypothesis: It is hypothesized that the immuno-biology of MSC alters with extended 
ex vivo culture. To test this, we have conducted a thorough analysis of: (a) MHC-I 
molecule expression; (b) the immunogenicity of cultured MSC; and (c) the immune 
modulatory activity of cultured MSC. To investigate the underlying mechanisms that 
mediate differences in MSC immune properties, we have conducted an analysis of: (d) 
cytokines secretion profiles; and (e) the response of allogeneic lymphocytes 
 xvii
stimulated in the presence or absence of cultured MSC. 
 
Experimental design:  
(a) Derivation and expansion of MSC subpopulations from C57BL/6 murine bone 
marrow, followed by the characterization of MSC and an analysis of their biology. 
Our initial focus was aimed at identifying an appropriate MSC subpopulation for 
subsequent immunological testing. 
(b) The MSC were then analyzed for MHC-I molecule expression, induction of 
allogeneic primary immune response, inhibition on ongoing allogeneic immune 
response and proliferation at increasing passage numbers in vitro. The immune 
modulating cytokine candidates (TGF-β and IL-10) from MSC were measured in 
these reactions. MSC at specific passage numbers were then selected for further in 
vivo testing. 
(c) Detection of MHC-I molecule expression, induction of allogeneic immune 
memory, and inhibition on the secondary immune response of MSC grafts at 
representative passage numbers in vivo. The efficacy of the cytokine candidates 
(TGF-β and IL-10) in the inhibitory reactions of MSC was further examined. 
Other pro and anti-inflammatory immune cytokines and immune cell components 
in sera were also evaluated. 
 
A summary of our results: Step (a) We identified an MSC subpopulation derived 
from C57BL/6 mice bone marrow following a 1 hour-silica incubation and negative 
 xviii
cell sorting that were plastic-adhesive, and negative in their expression of 
hematopoietic cell markers, but positive in the expression of MSC makers. These cells 
exhibited a good tri-lineage differentiation potential, and a normal karyotype along 
with long-term in vitro expansion and a fast growth rate. In addition, these cells 
displayed many of the standard biological features associated with MSC including 
good organ localization in vivo.  
Step (b) We demonstrated that this MSC subpopulation did not change the 
expression intensity of surface MHC-I during prolonged culture. However, in an in 
vitro surrogate for allogeneic immune responses termed a mixed lymphocyte reaction, 
the MSC exhibited a gradual change from an inhibitory phenotype to an inducing 
phenotype. In co-culture with naive BALB/c spleen mononuclear cells as the 
allogeneic responders, we found this change taking place from passage number 5 to 
14 (P5-P14). However, immune inhibitory activity was retained on ongoing 
allogeneic immune responses and Concanavalin A-mediated proliferation of 
allogeneic T cells by MSC at all tested passage numbers. Blocking of TGF-β and 
IL-10 partially removed the inhibitory effect of MSC on ongoing allogeneic immune 
responses and was associated with an increase in the expression of pro-inflammatory 
cytokines in the culture supernatant. Based on these results, we determined that MSC 
at P8 which displayed low levels of immunogenicity and high levels of 
immuno-inhibition and MSC at P14 which showed high levels of immunogenicity and 
low levels of immuno-inhibition were the appropriate passages to represent the polar 
extremes of MSC immunobiology. As such, MSC at these passage numbers were 
 xix
selected for comparison in in vivo testing.  
Step (c) MHC-I molecules were detected in MSC grafts 12 days 
post-implantation. MSC at both P8 and P14 were able to induce limited allogeneic 
immune memory of a similar magnitude. Lymphocyte infiltration was also observed 
in MSC grafts. However, MSC at P8 displayed a potent inhibitory effect on the 
secondary immune response in the graft microenvironment, while only 
chamber-constrained MSC at P14 displayed a similar magnitude of inhibition of the 
secondary immune response. We found that these inhibitory effects did not require the 
presence of MSC at the challenge sites or other proximal areas. In addition, blocking 
TGF-β and IL-10 did not significantly abolish the inhibitory effect of MSC secretion. 
IL-6 was found to be up-regulated in the sera of BALB/c mice which were 
significantly inhibited by MSC. Both MSC at P8 and chamber-constraint MSC at P14 
displayed significant inhibition on the proportion of lymphocytes in blood and the 
lymphocyte infiltration at allogeneic MNC challenge sites. MSC at P8 displayed 
stronger inhibition on the proportion of lymphocytes in spleen MNC. 
 
Conclusions: In summary, the diminishment of immuno-privileged and 
immuno-suppressive properties with increasing passage numbers is an innate 
alteration of MSC biology. The decrease in immuno-inhibition of MSC with 
increasing passage numbers can be explained by the appearance of immunogenicity 
and the reduction in inhibiting immune responses through soluble immuno-inhibitory 
cytokines. The increase in the immunogenicity of MSC could not be attributed to 
 xx
 xxi
MHC-I expression ex vivo. Aside from blocking the maturation, activation and 
proliferation of T lymphocytes as previously reported, MSC may have an additional 
inhibitory effect on the migration of T lymphocytes. This effect was probably 
mediated by multiple secretory molecules, involving TGF-β and IL-6 in a paracrine or 
endocrine manner.  
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Since the clinical application of stem cells was implemented decades ago, the safety 
of stem cell therapy has attracted intensive investigation. As autologous cell sources 
are limited, allogeneic stem cells have been proposed as an alternative and play a 
major role in current cell therapy. For instance, allogeneic hematopoietic stem cell 
transplantation is used to treat leukemia and other hematopoietic malignant disorders. 
Immuno-safety of allogeneic stem cell transplantation has always been problematic 
with graft-versus-host disease (GvHD) often reported. In this decade, progress has 
been made towards delineating the immune properties of mesenchymal stromal cells 
(MSC). It has been found that these stem cells are immuno-privileged and 
immuno-inhibitory. Besides these immune advantages, these cells possess 
multi-lineage differentiation ability in common with other stem cells and pose less 
ethical barrier. This has generated interests in applying them in tissue/organ 
regeneration and immune therapy. To draw a clear picture of the characteristics of 
MSC and their immune properties, this chapter will 1) briefly introduce a general 
conception of stem cells, followed by reviewing 2) the biology of MSC, 3) the current 
progress in immunological study of allogeneic MSC, and 4) the application potentials 
of MSC. Finally, 5) a background of the animal models used was provided. 
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1.2 WHAT ARE STEM CELLS 
 
1.2.1 Definition of stem cells 
 
Stem cells were traditionally defined as undifferentiated cells capable of 
self-maintenance, production of a large number of differentiated and functional 
descendants, tissue regeneration as well as proliferation [Potten 1990]. The focuses of 
this first definition were the undifferentiating status, the regenerative property and the 
ability of keeping stable cell numbers (self-maintenance) by stem cells themselves. 
Although it was suggested that stem cells should be a biological function rather than a 
discrete cellular entity that can be engaged by diverse cells to generate differentiated 
cells at the final residing milieu [Schofield 1983; Blau 2001], ‘stem cells’, as a 
cellular population with special functions, is widely accepted and used in practice. 
Moreover, they are further defined as a group of cells at an undifferentiated stage 
capable of self-renewal and pluripotent differentiation [Morrison 1997; Pamela 2000]. 
This popular definition emphasizes the rejuvenation (self-renewal) of stem cells 
instead of the maintenance of cell numbers in the previous concept. 
 
1.2.2 History of stem cells 
 
Although the definition of stem cells was clearly stated in 1990s, the first speculation 
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about stem cells was in 1867 that Cohnheim, a German pathologist, hypothesized the 
repair of mouse wound by bone marrow derived fibroblast-like cells [reviewed by 
Prockop 1997]. It was until 1961 that the first direct evidence about the existence of 
stem cells was found by Till and his colleagues. They observed that single cells 
isolated from bone marrow could completely reconstitute the hematopoietic system in 
lethally irradiated mice [Till 1961; Becker 1963; Siminovitch 1963]. From then on, 
the research of stem cells expedited. Various stem cells derived from tissues and 
organs all over the body were reported one after the other, and they were firstly found 
in animals, then in human beings. For example, mouse liver stem cells were found in 
1965 [Tayler 1965], mouse bone marrow non-hematopietic stem cells were found in 
1966, rat brain stem cells were reported in 1968 [Louise 1968], monkey 
spermatogonial stem cells were reported in 1969 [Clermont 1969] etc. It was in 1978 
that human HSC were isolated from cord blood by Prindull and Ueno [Prindull 1978; 
Ueno 1981]. Similarly in a chronological sequence, mouse embryonic stem cells 
(ESC) were derived from the inner cell mass of mouse blastocysts in 1981 [Martin 
1981; Evans 1981], and the derivation of human ESC was first reported in 1994 
[Bongso 1994], the mature culture protocol was published in 1998 [Thomson 1998]. 
Man-made embryonic stem cell-like stem cells were produced from adult cells by 
gene transfection recently. These cells are called induced pluripotent stem cells (iPSC) 
and overcome the ethical problem of ESC whilst allowing the creation of 
individual-customized stem cells a possibility. Similarly, these cells were firstly 
reprogrammed from mouse fibroblasts in 2006 [Takahashi 2006], then reprogrammed 
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from human fibroblasts in 2007 [Yu 2007]. This discovery represents a giant stride 
forward for the study of ESC. 
 
1.2.3 Common characteristics of stem cells 
 
So far, there are no uniform surface markers to identify all types of stem cells. 
However, various types of stem cells present three fundamental properties, i.e. 
long-term self-renewal, unspecialization and multiple differentiation potential.  
Long-term self-renewal is the ability of stem cells not only to maintain their cell 
numbers but also to pass their non-specialized property to descendants over long 
periods (many months to years, depending on the specific type of stem cell). This 
rejuvenation is realized by asymmetric division, which stem cells give rise to cells 
that are identical to them and to cells with more specialized functions [Wolpert 1988; 
Morrison 1997]. This property is believed to be essential to keep error-free 
proliferation of stem cells, as any genetic error at this level will lead to abnormal 
differentiation and cellular dysfunction of their descendants. 
Unspecialization is another basic property of stem cells which means the 
undifferentiating status of cells. Since these cells are ancestors of terminally 
committed cells, they lack differentiation markers, tissue-specific structures and the 
specialized functions of committed cells. For example, although ESC can be induced 
to various cardiovascular cells [Narazaki 2008; Matsuoka 2009] expressing CD31 
(endothelial cell marker) and working with neighbor cells to pump blood, ESC 
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themselves don’t express CD31 and can not perform blood-pumping function. 
Multiple differentiation potential is the remarkable property of stem cells which 
distinguishes them from other cell types. It covers the ability of stem cells to become 
more than one tissue- or organ-specific parenchymal cell type with special function 
after induction of various external and internal signals. These external signals can be 
physical contact with neighboring cells, chemicals secreted by other cells and 
molecules in the milieu. This property provides a theoretical basis for cell-based 
therapy with stem cells in regenerative medicine.  
Besides these three fundamental properties, stem cells showed other common features, 
such as slow cell cycle, distinct epigenetic gene profile from mature progeny [Ivanova 
2003], a long life span equivalent to the life of residing organism etc. 
 
1.2.4 Classification of stem cells 
 
Traditionally, there are two major methods to categorize various stem cells [Can 
2008]. According to their plasticity and developmental potential, these cells can be 
classified as totipotent, pluripotent and multipotent stem cells [Fortier 2004; Can 
2008]. A totipotent stem cell can give rise to an entire functional organism in an 
appropriate maternal environment. As far as we know, totipotent stem cells are the 
cells of the spherical embryonic mass of blastomeres before the blastula stage. A 
pluripotent stem cell can give rise to all cell types of three germ layers but not an 
entire organism. This is because pluripotent stem cells are able to form 
- 5 - 
LITERATURE REVIEWS                                                                 H. LIU 
extraembryonic tissues including umbilical cord and trophoblast [Thomson 1998] but 
not placenta and yolk sac [Bongso 2005]. This group of stem cells is derived from 
inner cell mass at blastocyte stage, epiblast layer at gasturala stage and three germ 
layers of embryos. A multipotent stem cell can give rise to more than one cell type of 
a single tissue. Developmentally, multipotent stem cells differentiate from pluripotent 
stem cells, and their offspring are progenitors of each specialized cell type. These 
cells are thus called tissue-specific stem cells and are named after their residing 
tissues, such as neural stem cells, HSC, hepatic stem cells etc. The differentiation 
pathway of stem cells has been summarized and shown in Figure 1 and Table 1 
[extracted from Can 2008]. 
According to their origin, stem cells can be classified to 2 broad categories: ESC 
and adult stem cells [Can 2008]. It is easy to understand that ESC are stem cells 
derived from embryos, including totipotent and pluripotent stem cells. And adult stem 
cells are derived from fetuses, cord blood and postnatal individuals. They are 
multipotent stem cells.    
However, due to the establishment of iPSC, there might be a new method to 
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1.3 WHAT ARE MESENCHYMAL STROMAL CELLS 
 
1.3.1 Definition of mesenchymal stromal cells 
 
MSC are a group of multipotent adult stem cells which have been reported to be 
derivable from diverse tissue sources, such as epidermis, intestine, bone marrow, liver, 
heart, kidney etc [Bobis 2006]. MSC derived from bone marrow have been most 
extensively studied and most conclusive data are based on the study of MSC from this 
origin. Therefore, this study focuses on MSC derived from bone marrow.  
In previous studies, MSC have been called many other names, including very small 
cells [Colter 2001], long-term culture colony-forming cells [Lanza 2001], bone 
marrow stromal cells [Ciapetti 2006], multipotent adult progenitor cells, 
mesenchymal stem cells, tissue committed stem cells, pluripotent stem cells 
[Ratajczak 2004], mesenchymal progenitors [Esposito 2009] etc. The variation in the 
nomenclature is based on different methods of isolation, expansion and 
characterization of the cells derived by different laboratories, as well as the 
understanding of variance in ‘stem cells’.  
To overcome the confusion and standardize the cell nomenclature, the Mesenchymal 
and Tissue Stem Cell Committee of the International Society for Cellular Therapy 
made minimal criteria to define MSC in 2006 [Dominici 2006]. In the proposal, it 
defines that MSC should adhere to plastic and have multipotent differentiation 
potential. The multipotency of MSC represents the ability to differentiate into 
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osteoblasts, adipocytes and chondroblasts under specific inducement in vitro. 
Osteogenesis should be shown by alizarin red or von kossa staining, adipogenesis by 
oil red O staining, and chondrogenesis by alcian blue staining or collagen type II 
immunohistochemistry staining. The criterion published by the Mesenchymal and 
Tissue Stem Cell Committee also described human MSC by negative expression 
(<2% of the cell population) of CD45, CD34, CD14/CD11b, CD79α/CD19 and 
human leukocyte antigen (HLA) class II, as well as positive expression (>95% of the 
cell population) of CD105, CD73 and CD90. However, the proposal also clarified that 
the surface antigen profile was not applicable to non-human systems because it is not 
universally well characterized in other species, such as mice. 
 
1.3.2 Heterogeneity of mesenchymal stromal cells 
 
Nowadays, the scientific consensus is that MSC are a highly heterogeneous cell 
population in terms of morphology, growth rate, differentiation potential and 
phenotype. This heterogeneity is intrinsic and unrelated to donor species, donor age, 
type of culture media, initial seeding density of MSC or freeze-thaw procedure 
[Rhodes 2004]. 
MSC are a minority cell population in bone marrow, approximately 0.01%-0.001% of 
mononuclear cells [Zohar 1997; Phinney 1999; Koç 2001; Minguell 2001]. After 
adherence to plastic, MSC display three morphologies: very small round cells, 
spindle-shaped cells (or fibroblast-like shape) and large flat cells. The very small 
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round cells are 7-10μm in diameter and have a high nucleus-to-cytoplasm ratio. Some 
of them have no granules, while the others have granules in the cytoplasm. 
Spindle-shaped cells and large flat cells are 15-50μm in diameter. They have 
vacuolated cytoplasm with moderate granules and frequently two large nucleuses. By 
Ki-67 staining, it was found that cells with granules in the cytoplasm were in cell 
cycle, whereas cells without granules were in a quiescent state [Bianco 2000]. In 
detail, the division-active MSC were 79.7+2% of whole population and the quiescent 
MSC were around 3.5+0.9% to 20% [Conget 1999, Tormin 2009].  
Although much of the available evidence indicates that MSC are in active division, 
their growth kinetics displays heterogeneity. By colony-forming unit assay at very low 
plating density, those colonies from rapidly dividing cells are big, tight and round, 
while those colonies from slowly dividing cells are small, dispersed and elongated 
[Digirolamo 1999; Horn 2008; Tormin 2009].  
The differentiation potential of MSC also displays great heterogeneity. This activity is 
unrelated to the various tissue/organ types of fetal or adult donors [in 't Anker 2003]. 
When the clonal analyses described above are applied to MSC, they are found to be 
cells at different developmental stages, involve multi- and bi-potent progenitors, 
lineage restricted precursors, and a small percentage of fibroblasts [Phinney 2007]. 
Most of the identified clones (60-80%) have an osteo-chondrogenic potential, and 
about one third of the clones have tri-lineage potential. However, there is none with 
differentiation potentials limited to the osteo-adipogenic or to the chondro-adipogenic 
lineages, nor pure chondrogenic and adipogenic lineages [Digirolamo 1999]. With 
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increasing cell doublings, MSC progressively lose their early progenitor properties, 
such as proliferation rate and multi-differentiation potential [Digirolamo 1999, 
Muraglia 2000, Banfi 2000]. Not all of MSC with high osteogenesis activity in vitro 
can form ectopic bone in vivo [Banfi 2000, Phinney 2007].  
In in vitro culture, MSC can vary in their phenotype while appearing homogeneous by 
light microscopy [Dominici 2006]. In order to rapidly identify and isolate pure MSC, 
their surface antigen profile has been widely studied. So far, it has been revealed that 
a large number of antigens characterized for other cell types, such as adhesion 
molecules, extracellular matrix proteins, as well as cytokines and growth factor 
receptors are expressed by MSC [summarized in Table 2]. However, no single specific 
marker of MSC has been identified. By analyzing different combinations of surface 
molecules, a variety of subpopulations of MSC have been identified, which are 
involved in different roles in tissue homeostasis and can contribute to various 
therapeutic applications other than their stem-like characteristics [Bobis 2006, 
Phinney 2007]. Although the co-expression of CD105, CD73 and CD90 has been 
defined as one of the minimal criteria of human MSC by the International Society for 
Cellular Therapy, this criterion was established based on the study of extensively 
cultured MSC. It was reported that the most discriminative markers for non-expanded 
human MSC were CD73 and CD49a, as all the colonies (100%) formed after bone 
marrow adherence for 1-3 days were CD73 positive and most (95.2%) were CD49a 
positive [Boiret 2005]. However, only 45.4% and 49% of the colonies were positive 
for CD105 and CD90 respectively. In other studies, STRO-1 was postulated to be 
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exclusively expressed by primitive mesenchymal precursors [Dennis 2002, Gronthos 
2003]. However, the STRO-1+ population in fresh bone marrow mononuclear cells 
exhibited a heterogeneous pattern of STRO-1 expression, with the majority of cells 
exhibiting low to intermediate levels of STRO-1 binding in addition to a small 
subpopulation of very high level STRO-1 staining cells. Among them, only those 
strong STRO-1-expressing cells that co-expressed CD106 and approximately half of 
these STRO-1+CD106+ cells had the ability to form colonies in vitro [Gronthos 2003]. 
Furthermore, within the colony-forming STRO-1+CD106+ cells, their tri-lineage 
forming abilities displayed diversity. This suggests that various subpopulations may 
be subsequently identified and separated. However, opposite suggestion was proposed 
that those rapidly self-renewing cells did not present STRO-1, but vascular 
endothelial growth factor receptor-2, tyrosine kinase receptor, transferrin receptor, 
annexin II (lipocortin 2) and CD117 [Colter 2001].  
 
Table 2. Summary of Negative and Positive Expression of Surface Molecules on 
MSC 
 
Marker Types Designation References 
Antigens 
Characterized for 
Other Cell Types 
CD101, CD13, CD59, CD73, CD81, 
CD901, CD124, CD147, Stro-1, Sca-1, 
1B10,  α-smooth muscle actin, 
MAB1740, SSEA-I, Flk-1, Oct-4, 
Rex-1, MHC-I1 
Minguell 2001; Pittenger 1999;  
Koç 2001; Heath 2000; Stenderup 
2001; Jiang 2002; Deschaseaux 












Pittenger 2001; Krampera 2006. 
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Extracellular Matrix Collagen type I, III, IV, V and VI; 
Fibronectin, Laminin, Hyaluronan, 
Proteoglycans, Vimentin 




CCR1, CCR2, CCR4, CCR7, CCR9, 
CCR10, CXCR1, CXCR3, CXCR41, 
CXCR5, CXCR6, CX3CR1 
Deschaseaux 2003; Bobis 2006; 
Granero-Molto 2008; Karp 2009. 
Adhesion Molecules CD29, CD441, CD49a, CD49b, CD49c, 
CD49e, CD49f, CD51, CD58, CD61, 
CD102, CD104, CD105, CD106, 
CD157, CD1661, αvβ3, αvβ5, VLA-1, 
VLA-4(CD49d/CD29), VLA-5 
(CD49e/CD29) 
Minguell 2001; Devine 2001; Gao 
2001; Deschaseaux 2003; Tocci 
2003; Majumdar 2003; Pittenger 




CD1a, CD32, CD11b, CD14, CD19, 
CD33, CD342, CD43, CD45, CD56, 
CD68, CD79α, CD1172, CD133, 
MHC-II2, Myoglobin 
Minguell 2001; Pittenger 1999; 
Koç 2001; Heath 2000; Devine 
2001; Jiang 2002; Krampera 2006.
Receptors CD25, CD95, CD122 Pittenger 2001; Krampera 2006. 
Costimulatory 
Molecules 
B7-1, B7-2, CD80, CD86, CD40, 
CD40L 
Devine 2001; Tocci 2003. 
Negative 
Expression 
Adhesion Molecules CD11a, CD11c, CD15, CD18, CD312, 
CD49d, CD502, CD542, CD62E, 
CD62L2, CD62P, PSGL-1 
Majumdar 2003; Pittenger 2001; 
Bobis 2006; Krampera 2006; Karp 
2009. 
1 The expression is controversial, but most opinions are for positive expression; 
2 The expression is controversial, but most opinions are for negative expression. 
 
1.3.3 Homing of mesenchymal stromal cells 
 
MSC express variety of chemokine receptors, adhesion molecules, and matrix 
enzymes, which confer organ/tissue homing ability. MSC homing is currently defined 
as the arrest of MSC within the vasculature of a tissue (localization), followed by 
transmigration across the endothelium [Karp 2009]. It is the theoretical base that MSC 
will migrate to and engraft in the target tissue to exert functional effects. When MSC 
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are systemically administered into a normal unperturbed animal by intravenous 
injection, they will appear in lung, liver, bone marrow and spleen within 8 hours, then 
gradually distribute to other tissues/organs, such as gut, kidney, thymus, skin etc [Gao 
2001, Devine 2003, Sordi 2009]. However, this does not appear to be the case when 
inflammation and injuries are present. In these circumstances, MSC preferentially 
accumulate in the inflamed and injured sites. Such cases have been widely 
documented in the therapy of radiation-induced multi-organ failure, ischemic brain 
injury, myocardial infarction, pulmonary fibrosis, acute renal failure, osteogenesis 
imperfecta etc [Bobis 2006, Brooke 2007, Granero-Molto 2008, Karp 2009]. 
Although the homing mechanism of MSC has not been fully understood, it is 
proposed to involve a complex multistep process similar to the molecular mechanisms 
for leukocyte migration. 
 
1.3.3.1 Mechanism of MSC homing 
 
The mechanism model of MSC homing after systemic administration includes 
continuous release of MSC-chemoattractants from tissue or endothelium; deceleration 
of MSC in blood stream; firm adhesion of MSC to endothelium; and transmigration of 
MSC across the vasculature.  
Chemoattractant release. The study on the chemokines and growth factors, which 
attract the traffic of hematopoietic cells, provides some good candidates for MSC 
migration, such as stromal cell derived factor-1 (SDF-1), monocyte chemotactic 
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protein-1 (MCP-1), MCP-3, PDGF-AB, insulin-like growth factor-1 etc 
[Granero-Molto 2008, Sordi 2009, Karp 2009]. In adult animals, the expression of 
SDF-1 is upregulated in the bone marrow endothelial cells and in ischemic tissues; 
MCP-1 is typically expressed at inflamed sites; and MCP-3 is induced in injured sites. 
MSC are found to express the receptors with high affinity to these chemoattractants, 
including CCR1, CCR2 (receptors for MCP-1 and MCP-3), CXCR4 (receptor for 
SDF-1), PDGF-receptor (R) α, PDGF-Rβ, IGF-R etc [Bobis 2006, Sordi 2009]. These 
chemoattractants released from tissue or endothelial cells not only mediate MSC 
homing to specific sites, but also promote activation of adhesion ligands, 
transendothelial migration, chemotaxis, and/or subsequent residence in target tissues 
[Karp 2009].  
Deceleration of MSC in blood stream. This is the initial step of MSC homing. The 
events to decelerate MSC within the vasculature are likely to involve tethering and 
rolling upon activated endothelium in bone marrow, inflamed tissue or injured sites. 
These weak interactions are mediated by CD44 expressed on MSC and E- and 
P-selectin (CD62E and P) constitutively expressed by endothelial cells [Brooke 2007, 
Karp 2009].  
Firm adhesion of MSC to endothelium. Following selectin-mediated tethering and 
rolling, MSC will arrest and firmly adhere to endothelium by the binding of VLA-4 
and CD44 on their surface to VCAM-1 and CD29 on endothelium [Brooke 2007, 
Karp 2009, Granero-Molto 2008] 
Transmigration of MSC out of the vasculature. Once firm adhesion has been achieved, 
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MSC will transmigrate through endothelium via the interaction of VLA-4 and 
VCAM-1. It is also suggested that the transmigration principle could be explained by 
diapedesis via the action of junctional adhesion molecules, cadherins and 
platelet-endothelial cell adhesion molecule-1 (CD31) [Brooke 2007]. Besides 
adhesion molecules, proteases secreted by MSC are essential to their invasive 
behavior during transmigration. These proteases include gelatinase, matrix 
metalloproteinase-2, tissue inhibitor of metalloproteinases, Membrane type-1 matrix 
metalloproteinase etc [Sordi 2009, Karp 2009]. Following successful transmigration, 
MSC will adhere to components of the extracellular matrix via α1 integrins and CD44. 
Migratory direction is regulated by a chemokine density gradient [Brooke 2007]. 
 
1.3.3.2 Factors influencing MSC homing 
 
There are some factors affecting MSC homing. The first factor that impacts homing is 
the size of MSC. With the necessary expansion of cell numbers in vitro, MSC will 
become larger and larger (approximately 20–60μm diameter) [Brooke 2007, Sordi 
2009]. The larger size causes them to be passively entrapped in capillary beds after 
infusion, particularly those of the lungs [Brooke 2007, Sordi 2009]. The 
administration of a vasodilator, such as sodium nitroprusside, was reported to increase 
the distribution of MSC in other organs other than lung. The second factor is the 
passage number of MSC. Both in vitro and in vivo evidences suggest that primary 
MSC home to bone marrow, spleen, injured tissues and ischemic sites more efficiently 
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than those that have undergone in vitro propagation [Bobis 2006]. Certain surface 
receptors, such as CXCR4, are exclusively expressed on fresh MSC, but are lost 
during culture [Karp 2009]. The third factor is the cell density. Increased culture 
confluence will cause an upregulation of tissue inhibitor of metalloproteinases-3 so as 
to inhibit transendothelial migration [Sordi 2009, Karp 2009]. The fourth factor is the 
heterogeneity in MSC surface receptor expression. It is obvious that MSC expressing 
more homing related receptors of high affinity will exhibit increased homing. 
However, the heterogeneous MSC populations result in various observations both 
within and between studies of homing. The fifth factor is the properties of the media 
and incubation environment. It is found that the pretreatment with TNF-α will 
up-regulate the expression of cell-adhesion and chemokine receptors to decrease 
rolling velocities of MSC and promote firm adhesion [Karp 2009, Sordi 2009]. The 
last factor is the site of MSC delivery. There are two ways to introduce MSC, systemic 
administration and local infusion. For systemic administration, MSC can be injected 
intravenously (IV), intra-arterially (IA), intracardiacally, and intraperitoneally. IV 
injection is the least invasive. However, MSC of larger size are often entrapped within 
filtering organs by this method, and this entrapment can be effectively reduced by IA 
delivery. In models of cardiac infarction, IA and intracardiacal delivery show higher 
engraftment rates of MSC than other ways, while intraperitoneal delivery is more 
suitable for intrauterine therapy of MSC, such as for muscular dystrophy. Local 
infusion is a final method of delivery, which shows higher MSC engraftment in 
certain tissues of interest, such as muscle. However, limited diffusion of nutrients and 
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oxygen will often cause the death of cell grafts [Karp 2009].  
 
1.3.4 Paracrine effects of mesenchymal stromal cells 
 
The paracrine effect of MSC was initially proposed because of the findings that the 
recovery of injured tissues does not require the incorporation of MSC but their lysates 
or conditioned medium [Granero-Molto 2008, Uccelli 2008, Sordi 2009]. Currently, 
MSC are known to produce a variety of cytokines that are involved in angiogenesis, 
the survival of the surrounding hosting cells at injured sites, the growth of 
parenchymal cells (such as smooth muscle cells and brain cells), the mobilization and 
activation of both circulating and tissue-resident stem cells, the stabilization of the 
extracellular matrix, as well as the homeostasis of bone marrow. These cytokines 
include vascular endothelial growth factor, basic fibroblast growth factor, nerve 
growth factor, brain derived neutrophic factor, SDF-1, IL-6, granulocyte monocyte 
colony stimulating factor etc [Tang 2005, Bobis 2006, Phinney 2007, Cheng 2008]. 
MSC express the receptors for some of these cytokines and chemokines, like CCR9 
and CXCR4, which are proposed to operate in an autocrine manner at the same time 
[Bobis 2006]. Besides promoting the regeneration of impaired tissues, abundant 
evidence suggest that MSC cytokines, such as transforming growth factor (TGF)-β 
and hepatocyte growth factor (HGF) 1, also play a role in modulating the immune 
system and reversing GvHD. Furthermore, anti-tumoral and enhanced 
immuno-suppressive effect can be achieved by injecting the cytokines secreted by 
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transgene-engineered MSC, such as neuronal stem cells secreting IL-12, IFN-β etc 
[Cheng 2008, Granero-Molto 2008]. Thus to get greater functional benefit, strategies 
to enhance the paracrine effects of MSC may be employed in the next generation of 
cell therapies.  
 
 
1.4 PROGRESS IN IMMUNOLOGICAL STUDY OF MESENCHYMAL 
STROMAL CELLS 
 
Besides the multiple differentiation ability, homing, and paracrine capability, the next 
most attractive feature making MSC a promising cell source with therapeutic potential 
is their unique immune modulatory activity. Recent reports indicate that MSC are 
immuno-suppressive. This immuno-suppression is not MHC specific and affects a 
variety of immune cells from both the innate and adaptive immunity. Complex 
mechanisms are involved in this immuno-suppressive activity as shown in Figure 2 
[extracted from Uccelli 2008]. Both contact and soluble factors mediate MSC 
immuno-suppression. Here, the immunogenicity of MSC and mutual effects of 
individual immune cells with MSC are extensively reviewed. 
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1.4.1 Immunogenicity of mesenchymal stem cells 
 
The basic concept that allogeneic MSC are not immunogenic comes from their low 
expression of MHC-I as well as deficient expression of MHC-II and co-stimulatory 
molecules, including CD80, CD86, CD40 and CD40L, in vitro [Barry 2005, Siegel 
2009]. This presence of MHC-I on surface suggests that they will avoid natural killer 
(NK) cell activation; while the absence of MHC-II and co-stimulatory molecules 
expression implies that they will lack the antigen processing, presentation, and 
costimulatory machinery to activate a profound T helper cell response, as well as may 
contribute to tolerance by inducing T cell anergy. In addition, a central tolerance 
mechanism is proposed to explain that MSC bypass allogeneic rejection by migrating 
and differentiating into thymic epithelium [Barry 2005]. However, arguments exist 
that this central tolerance mechanism is unlikely to be the primary mechanism of 
allogeneic MSC survival. 
Indeed, there are reports that the expression of MHC-I and -II on MSC surface can be 
up-regulated in the presence of pro-inflammatory molecules such as IFN-γ or when 
seeded at high concentrations or after lineage differentiation [Le Blanc 2003, Barry 
2005, Wang 2006, Chen 2007, Romieu-Mourez 2007, Siegel 2009]. When MSC are 
seeded at high concentration with other cells bearing MHC molecules, they can obtain 
MHC molecules by an inter-membrane transfer mechanism or via nanotubule 
‘highways’, but not through direct expression of MHC proteins by the cell itself [Le 
Blanc 2003, Barry 2005]. In the presence of MHC molecules, MSC acquire the ability 
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of processing and presenting antigens to T cells. However, because of the deficiency 
of co-stimulatory molecules, MSC keep the immuno-privileged property [Le Blanc 
2003, Barry 2005]. Upon lineage differentiation, the co-stimulatory molecule B7 will 
present on MSC. At the same time, these differentiated MSC will induce the 
activation of dendritic cells (DC) by up-regulating CD83 expression on DC [Chen 
2007].  
 
1.4.2 Immune modulation by mesenchymal stromal cells 
 
As other reviewers summarized, MSC have an extensive inhibitory effect on various 
immune cells in both innate and adaptive immune responses. The observations and 
mechanisms involved in this effect on individual immune cell type will be 
demonstrated in detail. 
 
1.4.2.1 Effect on innate immunity 
 
The innate immune system comprises an evolutionarily older defense strategy that 
provides immediate and temporary defense against infection in a non-specific manner. 
In vertebrates, its major function includes the identification and removal of foreign 
substances, the recruitment of immune cells to sites of infection and inflammation, the 
activation of the complement cascade to amplify the immune responses and to 
promote clearance, as well as the activation of the adaptive immune system through 
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antigen presentation. The leukocytes involved in the innate immune responses are NK 
cells, eosinophils, basophils, mast cells, and the phagocytic cells including neutrophils, 
monocytes/macrophages and DC. Unlike many other cells in the body, most innate 
immune leukocytes are only produced by pluripotent HSC in bone marrow, but can 
not divide or reproduce on their own. To date, a number of investigations into 
immuno-modulation by MSC on innate immune leukocytes focus on NK cells, 
monocytes and DC, with only one report detailing the effect of MSC on neutrophils, 
and none refer to that on eosinophils, basophils and mast cells. 
 
1.4.2.1.1 Effect on natural killer cells 
 
It has been reported that MSC can suppress the proliferation and effector functions of 
NK cells through altering their phenotype and cytokine secretion. This suppression 
can be enhanced by an interaction of MSC with NK cells.  
Upon the stimulation of IL-2 and IL-15, resting NK cells are induced to proliferate 
greatly. When MSC are added into this culture system at the beginning of the 
stimulation, this proliferation can be sharply abrogated; while MSC added after the 
stimulation exhibit partial inhibition [Spaggiari 2006, Sotiropoulou 2006, Spaggiari 
2009]. The mechanism of this MSC-mediated inhibition has not been identified. It is 
conceived that prostaglandin E2 (PGE2) and TGF-β1 may collaboratively contribute 
to the interference of the NK cells proliferation. 
More complex observations and mechanisms are demonstrated in the inhibition of 
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MSC on the effector functions of NK cells, including cytotoxic activity and cytokine 
production. Upon the same stimulation of IL-12 and IL-15 in vitro as above, resting 
NK cells acquire strong cytotoxic activity and IFN-γ secretion. However, MSC can 
effectively prevent the occurrence of this activation when they are added into this 
culture system at the beginning of the stimulation, and can also significantly inhibit 
these activities of pre-activated NK cells. It was proposed that the MSC-mediated 
cytotoxicity inhibition acts through down-regulating expression of the activating NK 
receptors, such as 2B4, Natural killer cell p30-related protein (NKp30), NKp44, 
natural-killer group 2, member D (NKG2D), and adhesion molecule CD56, as well as 
via secreting HLA-G5, indoleamine 2,3-dioxygenase (IDO), PGE2 etc [Aggarwal 
2005, Spaggiari 2006, Sotiropoulou 2006, Spaggiari 2008, Selmani 2008]. Unlike the 
MSC-mediated inhibition of NK cells proliferation, TGF-β1 may not play a role in the 
inhibition of NK cells cytotoxicity [Sotiropoulou 2006]. 
Interestingly, contrary results were observed that NK cells did not compromise their 
cytotoxic effect when they encountered MSC in vivo [Uccelli 2008]. MSC can be the 
lysis target of pre-activated NK cells. There is some evidence that may explain this 
contradiction. Besides the low levels of MHC-I on surface, MSC present many other 
proteins, such as adhesion molecules (intercellular adhesion molecule-1) and ligands 
for the activating NK receptors (such as MHC class-I-related chain A, UL-16 binding 
proteins, poliovirus receptor, Nectin-2 etc). These molecules on MSC can bind to 
corresponding activating receptors on NK cells, including NKp30, NKG2D, DNAX 
accessory molecule 1 and lymphocyte function-associated antigen-1. At the initial 
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ligation stage, these intimate contacts triggered the NK-mediated killing of MSC by 
up-regulating the expression of CD69 and the release of IFN-γ and TNF-α by NK 
cells, as well as a strong intracellular calcium increase in NK cells [Poggi 2005, 
Spaggiari 2006, Stagg 2007]. Conversely, the release of IFN-γ by NK cells results in 
the enhancement of MHC-I expression at the MSC surface. The binding of MHC-I 
with the inhibitory NK receptors (such as CD94–NKG2 receptors and 
killer-immunoglobulin-like receptors) finally contributes to the inhibition of NK cell 
activation and the survival of MSC in the later stages [Stagg 2007]. 
 
1.4.2.1.2 Effect on monocytes and dendritic cells 
 
MSC have an intensely inhibitory effect on the differentiation of HSC and monocytes, 
as well as the generation, maturation, antigen presentation and migration of DC. 
In the presence of MSC, both HSC and monocytes were prevented from 
differentiation into immature DC (iDC) in vitro, even under the stimulation of 
granulocyte-macrophage colony-stimulating factor and IL-4 [Jiang 2005, Nauta 2006, 
Ramasamy 2007, Uccelli 2008]. This was caused by the down-regulation of cyclin D2 
and the subsequent blocking of monocytes and HSC from entering the G1 phase of 
cell cycle [Ramasamy 2007]. PGE2 but not IL-6 plays a major role in this inhibition 
[Spaggiari 2009]. Interestingly, HSC obtain signals from MSC to differentiate into 
antigen-specific regulatory T cells (Treg) through activation of the Notch pathway [Li 
2008]. 
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In the presence of MSC, the maturation of iDC was halted too. It was shown that 
multiple surface molecules and soluble molecules of iDC were inhibited, such as 
CD1a, CD40, CD80, CD83, CD86, HLA-DR, IL-12, and TNF-α [Barry 2005, Li 
2008, Siegel 2009]. Similar to iDC, CD11c and CD14 on mature DC were 
down-regulated by incubation with MSC. This down-regulation severely impaired the 
antigen presenting capability of DC to stimulate naive T cell proliferation. At the 
same time, the incubation with MSC polarizes mature DC toward a 
suppressor/tolerant phenotype, which secretes less TNF-α and more IL-10, resulting 
in an attenuated or regulatory T cell response [Jiang 2005, Barry 2005, Nauta 2006, 
Uccelli 2008, Siegel 2009]. PGE2 was reported to be involved in these alterations 
[Aggarwal 2005]. By blocking PGE2 and removal of MSC, both differentiation and 
maturation of DC could be restored [English 2008, Spaggiari 2009]. 
Being co-cultured with MSC, the response and migration of DC to the chemokines, 
CCL19 and CCL21, becomes less sensitive [Jung 2007, English 2008]. This lower 
response is related to the reduced expression of CCR7, the continued expression of 
the tissue anchoring protein E-cadherin, as well as the decreased activity of Rac1 and 
Cdc42 by DC following stimulation. It is well-known that both CCL19 and CCL21 
are important chemokines attracting DC to lymph nodes, and DC are allowed to leave 
the peripheral tissue by down-regulating E-cadherin. Meanwhile, Rac1 and Cdc42 are 
required for DC adherence, migration, and chemotaxis through the alteration of 
cellular actin cytoskeleton recomposition [Li 2008]. The impaired recruitment of DC 
to the local lymph nodes will result in the deficiency of presenting antigen to naive T 
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cells, and subsequent the failure to initiate an adaptive immunity. However, this 
inhibition is still reversible after removing MSC [English 2008] and is mainly 
mediated through secretory mechanism [Li 2008]. 
 
1.4.2.1.3 Effect on neutrophils 
 
Neutrophils are the most abundant immune cell type in body. MSC have been also 
shown to dampen the N-formyl-l-methionin-l-leucyl-l-phenylalanine-induced 
respiratory burst as well as to delay the apoptosis of resting and activated neutrophils 
efficiently. This protection of neutrophils is through the activation of the signal 
transducer and activator of transcription (STAT)-3 by IL-6 and independent of 
cell-to-cell contact. However, MSC can not alter the phagocytic activity, adhesion 
molecule expression and chemotaxis of activated neutrophils. It is proposed that 
MSC-mediated preservation of resting neutrophils helps to maintain their homeostasis 
in bone marrow and lung as well as prevent the excessive responses of activated 
neutrophils [Raffaghello 2008]. 
 
1.4.2.2 Effect on adaptive immunity 
 
The adaptive immune system is composed of lymphocytes and antibodies that are 
highly specialized in eliminating a specific pathogenic challenge. Adaptive immunity 
requires activation by the innate immune system. The adaptive immune response is 
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able to recognize and generate memory responses to specific pathogens or ‘non-self’ 
antigens or ‘missing-self’ antigens, and to maximize the attacks whenever the same 
pathogen or pathogen-infected/antigen-bearing cell is encountered. Once 
immunological memory forms, the adaptive immune system can confer long-lasting 
and rapid protection to the host.  
In this system, B cells and T cells are the major types of lymphocytes which are 
derived from the same HSC in bone marrow. T cells develop in the thymus and B 
cells in the bone marrow. Both of them experience 3 differentiation stages: before 
encountering cognate antigens, they are naive lymphocytes circulating in the 
lymphatic system; once being activated by the cognate antigens within the secondary 
lymphoid tissues, they shift to effector lymphocytes; after eliminating the antigens, a 
few surviving effector cells differentiate to long-lived memory lymphocytes, which 
will quickly turn into effector cells on subsequent antigen re-exposure. In function, T 
cells major in cell-mediated immune responses, whereas B cells are intimately 
involved in the humoral immune response. So far, the inhibitory effect of MSC on T 
cells has been much more intensively investigated than that on B cells. 
 
1.4.2.2.1 Effect on T cells 
 
MSC have a profound inhibitory effect on the proliferation, effector function and 
migration of T cells at all 3 differentiation stages. The immunological effect of T cells 
includes the amplification, regulation and memory of immune responses as well as 
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cytotoxicity. 
 
Inhibition of proliferation of T cells 
 
The inhibition of naive T cell proliferation has been reported in the stimulation 
systems of polyclonal mitogens, allogeneic cells and specific antigens. Similar to the 
differentiation inhibition of iDC, this inhibition is realized by arresting T cells in the 
G0/G1 phase of the cell cycle but not inducing apoptosis [Jones 2007]. The reduced 
expression of cyclin D2 and increased expression of p27kip1 are involved in this 
process [Glennie 2005, Ramasamy 2007, Siegel 2009]. Furthermore, direct contact of 
MSC and T cells determines the expression of different cytokine receptors and signal 
transduction molecules for cytokine signaling by T cells [Barry 2008]. The ligation of 
the inhibitory molecule programmed death 1 (PD-1) of T cells to its ligands (PD-L1 
and PD-L2) on MSC and overstimulation through TCR ligation were reported to be 
involved in this inhibitory response [George 2003, Auggello 2005, Glennie 2005]. In 
addition, upon the contact with T cells, MSC are induced to secrete nitric oxide which 
suppresses the phosphorylation of STAT-5, a transcription factor crucial for T-cell 
proliferation [Sato 2007]. Upon the interaction with MSC, the IL-2 receptor on T cells 
is down-regulated and inhibits the proliferation through modulating the cytotoxic 
T-lymphocyte antigen-4 signaling pathway [Glennie 2005]. However, mechanisms of 
inhibition by MSC vary in different stimulation conditions of T cells. With an 
allogeneic stimulus, increased IL-10 levels and decreased IFN-γ production by MSC 
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play a major role in the decreased proliferation of T cells. Under the stimuli of 
phytohemagglutinin, MSC decrease IL-2 secretion and IL-2R expression, and 
secreted prostaglandins are important in the inhibition by MSC [Rasmusson 2005, 
Uccelli 2008]. This divisional arrest or ‘anergy’ is independent of antigen presenting 
cells and CD4+CD25+ Treg [Krampera 2003].  
 
Inhibition of effector function of T cells 
 
Most T lymphocytes (>95%) express an α and β chain form of T cell receptor (TCR), 
and are referred to as αβ cells. αβ cells can be classified as CD4+ or CD8+ T cells. 
CD4+ T lymphocytes, or helper T cells (Th), are important mediators that establish 
and maximize the adaptive immune response through cytokine secretion; while CD8+ 
T lymphocytes, or cytotoxic T cells (CTL), are potent ‘killers’ that target viruses (and 
other pathogens)- infected cells, or tumor cells, or damaged or dysfunctional cells. 
After activation, Th cells amplify and modulate immune responses through 5 
progenies: Th1, Th2, Th3, Th17 and follicular Th cells. Among them, Th1 and Th2 
cells are the two basic mediators major in cell-mediated immunity and humoral 
immunity respectively. The Th1 cells are characterized by the production of IFN-γ, 
while the Th2 cells release IL-4.  
In an allogeneic immune response, MSC were found to inhibit the response by 
altering the surface activation molecules and cytokine secretion profile of Th and CTL, 
polarizing Th1 response to Th2 response, as well as increasing the ratio of Th to CTL 
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[Aggarwal 2005, Groh 2005, Li 2007, Uccelli 2008]. Upon the addition of MSC, 
down-regulation of surface activation molecules, such as CD25, CD38, and CD69, 
was detected on both allogeneic reactive Th and CTL cells [Groh 2005, Li 2008]. At 
the same time, decreased levels of IFN-γ and TNF-α, as well as elevated levels of 
IL-2, IL-4, IL-12, and TGF-β were produced by allogeneic Th cells [Jones 2007, 
Uccelli 2008]. It was proposed that TGF-β, leukemia inhibitory factor (LIF), HLA-G 
and HGF but not IL-10 from MSC are in part responsible for mediating this T-cell 
inhibition [Groh 2005, Nasef 2007, Bobis 2006]. Another cytokine, IL-6, increasing in 
the coculture, can induce unresponsiveness of Th cells to IFN-γ signals and induce a 
shift of Th1 to Th2 responses [Dienz 2009]. The second possibility is that MSC will 
produce IDO when they are exposed to existing IFN-γ in allogeneic immune 
responses. Furthermore, IDO degrades tryptophan for inhibition of allogeneic T cell 
response [Barry 2008]. The third suggestion is that MSC suppress the Rac1 and 
Cdc42 activities of T lymphocytes, which alter cellular actin cytoskeleton 
recomposition, subsequently affect T-lymphocyte polarization and activation [Li 
2008]. The fourth implication is that MSC increase the proportion of Treg, and these 
Treg further suppress allogeneic Th cells and CTL cells by direct contact [Li 2007, 
Augello 2007, Siegel 2009].  
There are a few suggested mechanisms that explain the elevated numbers of Treg 
induced by MSC. Firstly, the secretory molecules, PGE2, HLA-G5, and LIF, play an 
inductive role in the proliferation of Treg [Aggarwal 2005, Nasef 2008, Uccelli 2008]. 
Secondly, an increased release of IL-6 in the co-culture of MSC and allogeneic T 
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lymphocytes determines the generation of Th3 instead of Th17 in the presence of 
TGF-β [Dienz 2009]. Th3 cells produce large amounts of TGF-β after antigen-specific 
activation, and drive the differentiation of antigen-specific Foxp3+ Treg in the 
periphery to induce and maintain peripheral tolerance [Carrier 2007]. Thirdly, MSC 
are able to induce the production of IL-10 by plasmacytoid DC which trigger the 
generation of Treg [Aggarwal 2005, Maccario 2005]. Fourthly, MSC reserve the 
expression pattern of CD62L and CCR7 on Treg so as to increase their trafficking and 
homing to secondary lymphoid organs (SLO) to perform immunoregulatory functions 
[Li 2008]. 
It is found that the inhibitory effect exerted by MSC on naive T cells can be relieved 
once MSC are removed from the co-culture, but this does not happen when MSC are 
removed from the incubation with antigen-specific memory T cells [Krampera 2003]. 
So far, it is not yet clear why memory T cells are more resistant to the recovery from 
the inhibition by MSC. A more pronounced inhibition of IFN-γ production was 
observed on memory T cells than that on naive T cells under the influence of MSC.  
MSC also have an inhibitory effect on γδ T cells, a subset of T cells bearing γ and 
δ chains of TCR. Gamma-delta T cells are closely involved in the control of cancer 
and also play a role in GvHD, sharing the characteristics of Th cells, CTL and NK 
cells. MSC suppress the proliferation but not the cytotoxicity of γδ T cells [Petrini 
2009]. This suppression was observed on the expansion of T cells carrying 
Vgamma9/Vdelta2, which were induced by the combination of IL-2 and zoledronate. 
Similar to the inhibition of αβ T cells, this suppression is HLA-independent, 
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cell-to-cell contact and soluble factor mediated.  
 
Inhibition of migration of T cells 
 
In a murine acute GvHD (aGvHD) model, increased numbers of T lymphocytes stuck 
in the SLO after MSC infusion [Li 2008]. Upon further analysis, the majority of the 
higher number of T lymphocytes in SLO were of donor origin and of a 
CD62L+CCR7+ phenotype. The expression of CD62L and CCR7 is one of the features 
of naive T and central memory T cells, conferring them the ability of homing to SLO. 
Moreover, as reviewed above, MSC can inhibit the proliferation, cytotoxicity of T 
lymphocytes, as well as differentiate activated T lymphocytes to an anti-inflammatory 
phenotype. Thereby, it is deduced that MSC inhibit aGvHD through recruiting 
allogeneic T lymphocytes to the SLO and thus reducing their infiltration toward target 
tissues. So far, mechanisms involved in this inhibitory activity are unclear. It was 
found that the infused MSC unnecessarily presented in SLO when this migratory 
inhibition occurred. Therefore, the soluble molecules secreted by MSC, such as IL-6, 
would probably be the primary contributor to the altered migratory properties of T 
cells [Dienz 2009]. 
 
1.4.2.2.2 Effect on B cells 
 
As reviewed above, direct interactions of MSC with T cells result in an arrest of T-cell 
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proliferation, modulation of Th cell activity, inhibition of CTL-mediated cytotoxicity, 
as well as generation of Treg cells. Consequently, impaired Th cell activation would 
translate into defective T-cell help for B cells to proliferate and produce antibodies. 
These indirect effects on B cells might be reinforced by direct inhibitory activities of 
MSC on B cells. Indeed, the inhibitory effect on the proliferation, differentiation and 
migration of B lymphocytes by MSC has been observed and reported.  
It is demonstrated that the inhibition of B cell proliferation by MSC shares the same 
mechanism as the inhibition of T cell proliferation. Naive B cells are stopped at G1 
phase of the cell cycle by MSC in the presence of a combination of anti-CD40 
monoclonal antibody and IL-4 or a mitogenic stimulus or lipopolysaccharide [Glennie 
2005, Auggello 2005, Asari 2009]. Cyclin D2 is the common MSC target of both T 
and B cell split anergy. Soluble factors of MSC are the major mediators in the 
inhibition, but a direct cross-talk between B cells and MSC by soluble factors is a 
prerequisite to license MSC to perform their inhibitory function [Siegel 2009]. 
More data supporting the inhibitory effect of MSC on B lymphocytes focuses on B 
cell differentiation and immunoglobulin (Ig) production. In a coculture of MSC and B 
lymphocytes, the number of immature B cells increased, displaying a higher level of 
surface Ig, CD19 and CCR7 with lower levels of cytoplasmic and secretory Ig 
(including IgM, IgG and IgA), B-lymphocyte-induced maturation protein-1 and IL-5 
[Corcione 2006, Tabera 2008, Comoli 2008, Asari 2009]. This interference of B cell 
terminal differentiation can be induced by both T-cell dependent and independent 
antigens. Interestingly, MSC have no effect on the Ig secretion of B cells induced by 
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direct CD40-CD40L binding [Comoli 2008]. The modification of the phosphorylation 
pattern of the extracellular response kinase 1/2 and p38 mitogen-activated protein 
kinase pathways could partly explain this MSC-mediated B-cell inhibition [Tabera 
2008]. Another explanation for the reduced Ig production is through the initial step of 
enzymatic cleavage of CCL2 and CCL7 by matrix metalloproteinases of MSC, with a 
subsequent suppression of STAT3 activation, as well as the induction of transcription 
factor PAX5 expression, which finally leads to the reducing Ig synthesis in plasma 
cells [Rafei 2008].   
Besides the proliferation and differentiation, the chemokine receptors (such as 
CXCR4, CXCR5, and CCR7) of B cells are also down-regulated by MSC, suggesting 
impaired chemotactic activity of B cells [Corcione 2006, Siegel 2009]. This effect 
depends on the release of soluble factors and on cell–cell contact, such as the 
interactions between PD1 and its ligands [Uccelli 2008].  
 
1.4.3 Effect on mesenchymal stromal cells by immune system 
 
On studying the immune properties of cells from various tissues and 3 germ layers, it 
was revealed that the anti-proliferative effect is a fundamental and innate property 
shared by all stromal cells but not ectodermal, endodermal and most parenchymal 
cells [Jones 2007]. However, it is evident that the immune properties of MSC can be 
modulated by immune cells. This modulation can be categorized in 2 ways: one is to 
induce the expression of new surface and soluble immune molecules by MSC; the 
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other is to enhance the expression of anti-inflammatory cytokines which are 
constitutively released by MSC. Soluble factors from immune cells play a major role 
in both ways. 
Among various cytokines released by immune cells, IFN-γ is the most prominent 
soluble factor to modulate the immune activity of MSC. It was reported that low dose 
of IFN-γ induces the expression of MHC-II and intercellular adhesion molecule-1 by 
MSC, which confers MSC a conditional Ag-presenting function early in an immune 
response [Tse 2003, Stagg 2006, Chan 2006]. At the same time, IFN-γ could 
upregulate the existing MHC-I expression of MSC to protect them from NK-mediated 
killing [Spaggiari 2006]. However, with an increase of IFN-γ, this upregulation of 
MHC expression by MSC, together with the Ag-presenting function, would not be 
enhanced [Stagg 2006]. In addition, IFN-γ alone is crucial to induce the production of 
an important anti-inflammatory molecule, IDO, by MSC, which strongly inhibit the 
proliferation of T cells, NK cells and B cells [Meisel 2004, Krampera 2006, English 
2007, Ryan 2007, Spaggiari 2008]. Other reports demonstrated that IFN-γ alone has 
an inductive effect on HGF and TGF-β1 expression [Ryan 2007].  
In combination with cell contact and other pro-inflammatory cytokines, IFN-γ could 
perform a profound inducible function on the production of more anti-inflammatory 
factors. For example, the combination of IFN-γ and TNF can increase the constitutive 
production of PGE2 by MSC, assisting in the shift of Th1 response to Th2 response 
[Aggarwal 2005]. The combination of IFN-γ and TNF, IL-1α, or IL-1β, can trigger the 
production of inducible nitric-oxide synthase by MSC, synthesizing NO to inhibit the 
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proliferation of T and B lymphocytes as well as the activation of T lymphocytes 
[Chabannes 2007, Siegel 2009]. The same combination of cytokines also increases the 
production of chemokines by MSC that attract T cells [Uccelli 2008]. Besides IFN-γ, 
IL-1β from blood monocytes was reported to induce the secretion of TGF-β1 but not 
IL-10 by MSC, leading to the inhibition of T cell activities [Groh 2005]. The 
combination of IL-1α and TNF-α could elevate the constitutive secretion of LIF, IL-6 
and IL-8 by MSC, while IL-4 alone reduces the LIF secretion but has no effect on 
IL-8 synthesis. By contrast, IL-4 stimulates IL-6 synthesis [Denizot 1999]. 
In spite of the important role of pro-inflammatory cytokines in the modulation of 
MSC immunological behavior, MSC-to-immune cell contact also exerts a role. It was 
reported that the production of inducible nitric-oxide synthase could also be achieved 
in MSC by direct contact with activated Th cells or CTL cells [Sato 2007]. Full 
expression of the existing soluble anti-inflammatory factor, HLA-G5, by MSC 
requires cell contact with alloreactive T cells and IL-10 stimulation [Selmani 2008]. 
By expression of HLA-G5, MSC are able to suppress the proliferation of lymphocytes 
[Nasef 2007], inhibit the cytolytic activity of NK and CTL cells, shift the allogeneic 
Th1 to a Th2 response [Carosella 2003], and induce the expansion/generation of Treg 




In the last decade, immunological studies of MSC have made significant progress. It 
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has been shown that allogeneic MSC do not induce immune responses and have 
profound inhibitory effects on the proliferation, effector functions and migration of 
most types of immune cell. During an allogeneic response, MSC are modified by the 
secretion and by contact with immune cells. The resulting immune response 
represents a balance of the interaction between MSC and the allogeneic immune cells. 
However, what we understand about the immune properties of MSC remains limited. 
The molecular pathways of MSC immuno-modulation are poorly characterized. The 
lack of standardized methodologies for isolation and identification of MSC makes the 
results from different laboratories difficult to compare. Current studies are done on in 
vitro cultures of MSC, and hence there is an urgent requirement to extend these 
observations to versatile in vivo models.  
 
 
1.5 APPLICATION POTENTIALS OF MESENCHYMAL STROMAL CELLS 
 
Among all types of stem cells, adult MSC are the most promising cell source for 
emerging cell-based therapeutics in the near future. The application potential is being 
explored in various animal models and tested in clinical trials [Refer to 
http://clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells ]. 
 
1.5.1 Application of mesenchymal stromal cells 
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The clinical utility of MSC is due to their convenient isolation, their lack of ethical 
controversy, their deficiency of significant immunogenicity permitting allogeneic 
transplantation without immunosuppressive drugs, their capability of migrating to 
damaged and inflamed sites, and their potential to differentiate into tissue-specific cell 
types [Sasaki 2008, Toma 2002] with trophic activity [Zhang 2007]. In addition, they 
also have the potential to promote vascularization [Martens 2006] and have potent 
immunosuppressive effects with various secretory factors. Thus, MSC have been the 
focus of developing new therapies to regenerate damaged tissue and treat 
inflammation [Karp 2009].  
MSC support of hematopoiesis. After transfusion, MSC are able to home to bone 
marrow and create both ‘endosteal niches’ and ‘vascular niches’ for hematopoiesis by 
differentiating into pericytes, myofibroblasts, stromal cells, osteocytes, bone-lining 
osteoblasts, and endothelial cells. On the one hand, the presence of MSC in bone 
marrow contributes to the maintenance and self-renewal of HSC by sheltering them 
from differentiation and apoptotic stimuli. On the other hand, these niches support the 
expansion and differentiation of HSC, and control the release of mature progenies into 
the vascular system [Muguruma 2006, Kiel 2008, Meuleman 2009]. Therefore, an 
improved efficiency of successful HSC engraftment has been widely reported with the 
assistance of co-transplanted MSC [Kim 2004, Maitra 2004, Le Blanc 2007].  
MSC relieve GvHD and autoimmune diseases. MSC have a potent and long-term 
therapeutic effect on severe, steroid-refractory aGvHD which has no established 
remedy [Le Blanc 2004, Rignden 2006, Le Blanc 2008]. They are also good 
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candidates for treating autoimmune diseases, such as experimental autoimmune 
encephalomyelitis, collagen-induced arthritis, Crohn’s disease etc [Zhang 2005, 
Zappia 2005, Augello 2007, Karp 2009, Iyer 2009]. However, little is known about 
mechanisms of these therapeutic effects by MSC. As in vitro findings conclude, MSC 
are capable of interfering with the functioning of adaptive immunity and have various 
effects on immune cells. Therefore, the mechanisms may relate to the release of 
soluble immuno-inhibitory factors and the induction of Treg as summarized above.  
MSC assist organ transplantation. Animal models have shown that the 
co-implantation of MSC can markedly prolong the survival of allogeneic heart [Zhou 
2006] and allogeneic skin [Bartholomew 2002]. It is deduced that the reasons of MSC 
to prevent such acute rejections following solid organ transplantation may be their 
immunosuppression targetting inflammatory and alloimmune pathways, coupled with 
the ability for tissue repair of ischaemic damage [Brooke 2007, Popp 2009].  
MSC regenerate damaged tissue/organ. To regenerate tissue/organ defects has been 
believed to be the most important and attractive function of MSC in therapy. The 
efficacy of MSC in treating diabetes, myocardial infarction, brain and spinal cord 
injury, acute renal and hepatic failure, acute lung injury, as well as cartilage and bone 
injury has been widely reviewed [Bobis 2006, Brooke 2007, Granero-Molto 2008, 
Uccelli 2008]. Given the ease of their isolation, their extensive proliferation rate and 
differentiation potential, as well as a possible homing ability, MSC may provide a 
niche that not only controls immune responses, but also regulates the survival and 
expansion of resident parenchymal cells [Jones 2007]. These deduced mechanisms 
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come from the observations that limited levels of MSC engraftment and 
transdifferentiation can be detected in injured tissues, while they could produce plenty 
of important growth factors and trophic cytokines which benefit local cell survival, 
expansion and angiogenesis [Le Blanc 2006, Uccelli 2008]. 
MSC facilitate gene therapy. Due to the high gene-transfer efficiency [Drize 1992, 
Bartholomew 2001] and long-term survival after engraftment [Pereira 1995], MSC 
have been proposed to be an excellent potential tool for delivering secreted and 
biologically active gene product to correct enzyme/protein defects, to promote tissue 
repair, to carry anti-tumor molecules, and to alleviate inflammation [Verfaillie 1998, 
Reiser 2005]. Successful cases are reported in delivering erythropoietin [Bartholomew 
2001], treating diabetes [Xu 2007], haemophilia [Chuah 2000, Van Damme 2003], 
osteogenesis imperfecta [Horwitz 2001], Parkinson’s disease [Schwarz 1999], 
intracranial glioma [Nakamizo 2005, Hong 2009], and accelerating cardiac repair 
after myocardial infarction [Mangi 2003] by transgenic MSC in animal models and 
pre-clinical trials. In addition to these clinical applications, transgenic MSC are also a 
good tool to better understand the mechanisms beneath these therapeutic benefits, 
such as marking these cells with various track-reporting genes [Devine 2003, Dick 
2003, Hill 2003, Anjos-Afonso 2004].  
 
1.5.2 Limitation of mesenchymal stromal cells 
Although MSC have displayed several advantageous activities which facilitate the 
treatment of many refractory diseases, they also have some drawbacks that need to be 
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overcome to allow a wider clinical application. 
Unclear properties of MSC. One of the drawbacks lies in the elusive nature of MSC. 
So far, there is no specific marker to identify MSC from a heterogeneous cell 
population which is derived from various bone marrow culture methods. This 
heterogeneous cell population is believed to be a mixture of bona fide MSC and 
various progenitor cells. Clearly, the biology and function of the expanded MSC are 
different from those of the fresh or original unmanipulated MSC [Uccelli 2008, 
Reister 2009]. It is unknown how and to what extend these impure cells affect the 
results of MSC in therapy. Obviously, the purity of MSC will cause fluctuating results 
in both in vitro and in vivo studies. 
Safety concern about MSC in therapeutic application. One of the key potential 
benefits of MSC for clinical application is a reduced risk of iatrogenic oncogenesis. In 
comparison with ESC, MSC are adult stem cells which have a limited life span, 
restricted proliferation ability and narrow differentiation spectrum. Unfortunately, a 
multifocal brain tumor was recently reported to occur when neural stem cells, another 
type of adult stem cells, were injected into a boy with ataxia telangiectasia [Amariglio 
2009]. This is the first case of a donor-derived brain tumor. It was proposed that 
patients with this particular disease have an impaired immune system and lose the 
ability to reject tumor cells. However, as mentioned above, MSC have inhibitory 
effects on immunity, so this raises the question - will this immuno-suppressive 
mechanism increase the risk from certain forms of tumor? Several studies have 
reported that MSC are able to promote tumor growth in allogeneic animal models 
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[Djouad 2003, Djouad 2006, Aggarwal 2005, Tolar 2007, Uccelli 2008]. It is 
explained that besides the interference of immunity, MSC are able to migrate to the 
tumor loci in response to the degenerative cues and form a cancer niche to promote 
the tumours potential for proliferation by providing growth factors [Ramasamy 2007, 
Granero-Molto 2008]. The fusion of MSC and local cells which leads to chromosomal 
abnomality may be another reason that relates to promotion of tumorigenesis [Spees 
2003]. Similar to the tumorigenesis mechanism, excessive immuno-inhibition of MSC 
could render the host vulnerable to infectious agents [Uccelli 2008]. The treatment 
with MSC for severe GvHD was associated with disseminating cytomegalovirus, 
varicella-zoster virus, adenovirus, and Aspergillus and Fusarium infections [Maccario 
2005]. Therefore, the safety of MSC for therapy should be assessed carefully.  
Inconsistent efficacy of MSC in therapy. Even though abundant studies demonstrate 
the feasibility of MSC as new therapeutic candidates, there is a lack of consensus 
regarding their efficacy. As reviewed, MSC can be used to alleviate severe aGvHD, 
while other reports have indicated that MSC can prevent but not treat GvHD [Tisato 
2007], and may even cause a higher incidence of relapses of GvHD after co-infusion 
[Ning 2008]. On the other extreme, the failure of MSC to prevent GvHD was also 
reported [Sudres 2006]. Other contrary examples that question the efficacy of 
MSC-mediated therapy include the observations on allogeneic MSC graft survival 
[Eliopoulos 2005], ability to support allogeneic hematopoiesis [Nauta 2006], role in 
tissue regeneration [Wakitani 2002, Ninichuk 2006, Popp 2007], prevention on the 
rejection of heart transplantation [Inoue 2006], maintenance of the serum level of 
- 44 - 
LITERATURE REVIEWS                                                                 H. LIU 
haematocrit by erythropoietin-gene transferred MSC [Eliopoulos 2005] etc.  
Low efficiency of MSC in therapy. Low efficiency is another problem identified in 
MSC-mediated therapy. Except for those unsuccessful engraftments, relatively small 
numbers of donor MSC grafts were retained in recipients’ tissues [Koç 2002, di 
Bonzo 2008]. The percentages of integrated MSC were as low as 0.1-0.23% after 3 
days’ infusion in liver for hepatocytic repair [di Bonzo 2008], 0.4-2% in bone marrow 
after 60 days of infusion for treating the Hurler syndrome  [Koç 2002], as well as 
1.5-2% in defected bone after 3 months of infusion for osteogenesis imperfecta 
therapy [Horwitz 2001]. So far, the highest percentage of MSC engraftment was 
described by Pereira, showing 1.5-12% of MSC graft in murine bone after 5 months 
of cell infusion [Pereira 1995].  
Short effective period of MSC in therapy. The evidence for clinical efficacy of MSC in 
different experimental models occurred usually during the acute phase of diseases 
[Uccelli 2008]. Pereira showed that a high percentage of MSC graft in bone could 
achieve an improvement of collagen and mineralization content could be achieved 
after 5 months of MSC infusion into a mouse model with osteogenesis imperfecta, but 
this effect was transient [Pereira 1995]. Among current observations of in vivo tests, 
most effective starting time points of MSC for therapy were around 7 days after being 
implanted [Brooke 2007], and the effective periods varied from 14 days up to slightly 
over 1 year [Coyne 2006, Le Blanc 2008]. 
The conflicting reports for therapeutic effects of MSC and the variability of 
successfully engrafted donor MSC may have several explanations, these include: i) 
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the diversity of MSC populations originating from donor tissue of different ages; ii) 
MSC derived using different isolation methods; iii) MSC cultured in different media 
environment; iv) MSC expanded for different time durations/passage numbers; v) the 
variation of recipients’ medical status in in vivo testing, involving different 
physiological, pathological, and immunological status; vi) the different techniques for 




1.6 ANIMAL MODEL 
 
To explore the allo-immunological safety of MSC, abundant ex vivo data have been 
collected. The deductions and hypothesis derived from these data require verification 
in animal models before proceeding to treatment of human diseases. However, there is 
no universal model to test all aspects of the immunological effect of MSC in versatile 
diseases. If an inappropriate animal model was chosen, the results and conclusions 
may not reflect accurately the situation in patients. The essential factors that influence 
the choice of an animal model for testing the immunological activity of MSC include 
the species and the physiology of the animal (such as the size, the age, the gender and 
the immune system features), the availability of research materials (such as antibodies, 
genetic information for gene-modification etc), the feasibility of surgical procedures 
and evaluation techniques, the costs involved etc [Watters 2001].  
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In the last decade, the species utilized for in vivo transplantation studies addressing 
the immunology of MSC involved mouse, baboon, rat, pig, sheep, guinea and dog. 
Among them, mouse was the most commonly used species; particularly inbred mice 
have made a major contribution to our understanding the MSC effect in adaptive 
immunity. By 2002, the full genomic sequence of the inbred C57BL/6 mouse had 
been completely drafted. Upon comparison, there are only 300 or so genes that are 
unique to mouse [Waterston 2002]. Those inbred mouse strains provide a more 
controllable in vivo environment targeting a particular immunological problem; the 
clear genome map of inbred mouse strains provides a useful tool for gene 
modification; and the similarity of mouse genome to human genome implies that 
mouse models are a good intermediate between mouse studies and clinical trials 
[Morse 2007]. For example, C57BL/6 and BALB/c mice are a pair of common inbred 
stains utilized in investigating allogeneic immune responses because of expression of 
mismatched or different MHC molecules; the former expresses H-2b, while the latter 
expresses H-2d [Quimby 2007]. Being inbred strains, the genetic background of these 
mice are stable and similar among siblings within the same strain, thus the in vivo 
experimental results derived can be easily replicated. Based on current results, the 
immuno-inhibitory effect of MSC on the allogeneic immune responses caused by 
splenocytes of these two mouse strains could also be observed on the same testing of 
other mouse strains and other species (including human beings), implying that the 
results derived from this pair of mouse models are representative.  
In addition to the above advantages, mice are animals which are easily bred and 
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handled. Mouse models of delayed-type hypersensitivity assay (DTH) are well 
established and are used to investigate cell-mediated immunity by measuring the 
swelling of their footpads or pinna of their ears with minimal invasion [Hughes 2007, 
Luo 2007]. Moreover, abundant commercial products are readily available for 
characterizing, isolating, culturing, labeling, detecting and analyzing murine cells. 
Due to the small size of mice, some technical approaches for humans have only been 
made possible by the miniaturization of equipments, such as CT, MRI, and PET. To 
ensure the correct appraisal of experimental outcomes, it is important to keep the 
gender and age of donors and recipients consistent during the whole experiment 
[Watters 2001, Bilbo 2001]. To induce a maximal immune response, the female mice 
at the sexual maturation period are preferred. 
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2.0 HYPOTHESIS AND OBJECTIVE 
 
Evidently, in vitro passage will exert a broad and intense effect on the properties of 
MSC [Rombouts 2003, Kretlow 2008, Roobrouck 2008, Izadpanah 2008]. 
Nevertheless, there is deficient of a systemic investigation on the relationship of ex 
vivo expansion and immuno-biology of MSC. And in previous reports, the passage 
numbers of MSC used for immunological studies are hardly indicated. To address 
these pressing questions, we hypothesize that the immunobiology of MSC will alter 
with extended ex vivo culture. Because the anti-proliferative effect of MSC is found to 
be a common immunological property of all stromal cells [Jones 2007], we also 
hypothesize that common alteration modes of immune properties may exist among 
different subpopulations of heterogeneous MSC. As summarized at the beginning of 
literature review, allogeneic MSC are an important substitute when autologous cell 
source is unavailable in some physiological and pathological conditions. Thus, the 
immunological safety of allogeneic MSC for clinical application is highly concerned. 
To address this safety issue, allogeneic MSC were used to investigate the alterations 
of immunobiology with increasing passage. And a delayed-type hypersensitivity 
animal model was used to verify the in vitro observations.  
Through this experiment, we aimed to observe the change of immune properties of 
allogeneic MSC and investigate possible mechanisms underlying the change. 
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3.1.1 Experimental design 
 
To achieve the goal, this experiment was designed in 3 steps. The first step was to 
establish a well-characterized MSC subpopulation as study subject. The second step 
was to test the immune properties of this MSC subpopulation at serial passage 
numbers in vitro. At the same time, the mechanisms which might be involved would 
be explored. The last step was to use a delayed-type hypersensitivity model to further 
verify the immune properties of the MSC subpopulation at a selected early and late 
passage numbers in vivo. At the mean time, the ex vivo mechanisms would be tested 
while the in vivo mechanisms would be explored. 
 
3.1.2 Experimental animals 
 
Because mice have many advantages for immunological studies as summarized in 
literature review, they were selected to be the testing species in this experiment. 
Female C57BL/6 and BALB/c mice, 6-8 weeks old, were purchased from the 
breeding colonies at the Laboratory Animals Center (Sembawang, Singapore). All of 
them were acclimatized under controlled temperature (25ºC), lighting (lights on from 
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7am to 7pm), and humidity (50–70%) in the satellite Animal Holding Unit of the 
National University of Singapore. All experimental protocols involving mice had been 
approved by the Institutional Animal Care & Use Committee of the National 
University of Singapore. 
 
3.1.3 Common materials and consumables 
 
Unless otherwise stated, all MSC media were purchased from StemCell Technologies 
Inc. at Canada. The complete MSC media (CM) was composed of MesenCult Basal 
Medium (Catalog# 05501, Lot# 07B21265) containing Mesenchymal Stem Cell 
Stimulatory Supplements (containing serum and pretested supplements defined by 
supplier, Catalog# 05502, Lot# 06M20759) and 1% Penicillin- Streptomycin solution 
(PS). The other basic media and reagents were purchased from the National 
University Medical Institutes Lab Supplies Store which prepared according to the 
formulas of Sigma-Aldrich (USA) or directly bought from Sigma-Aldrich. All 
monoclonal antibodies were purchased from Pharmingen and eBioscience of BD 
Biosciences (USA). All culture flasks were purchased from Techno Plastic Products 
(Switzerland); all culture plates, ELISA plates, centrifuge tubes, 0.2-µm pore-size 
96-well insert strips, 0.4-μm pore-size 24-well inserts, and 100-µm pore-size meshes 
were obtained from BD Falcon (USA) and Nunc (Denmark).  
 
3.2 CULTURE AND CHARACTERIZATION OF MSC 
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3.2.1 Isolation and culture of mouse bone marrow cells 
 
After C57BL/6 mice were sacrificed by CO2 asphyxiation, both femurs and tibiae 
were harvested and transferred back to the laboratory in CM. Then the surrounding 
soft tissues and the ends of each femur and tibia were removed to expose the bone 
marrow cavity (Figure 3). Bone marrow were flushed out from the cavities, and those 
of the same donor were cultured in 5ml of CM in one T25 flask at 37ºC, 5% CO2 and 
95% humidity for 3 days. Non-adherent cells were discarded, and adherent cells 
attained confluence after 3-5 days. The confluent cells were detached with 0.05% 
Trypsin/EDTA (Invitrogen, USA) at 37ºC for 2 min and neutralized with equal 
volume of CM. Detached cells were seeded at a split ratio of 1:2 for subsequent serial 
passage.  
 





Before flush After flush
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3.2.2 Enrichment and propagation of mouse MSC (mMSC) 
 
To optimize an appropriate mMSC subpopulation for further immunological study, 
there were 3 ways to isolate mMSC. One was to keep passaging attached bone 
marrow cells without any enrichment (M1, n=10) at a split ratio of 1:2 up to passage 
(P) 5, and a seeding density of 5×103 cells/cm2 after P5. Another was to incubate bone 
marrow cells of P2 (M2, n=7) with 100 μg/ml of silica microspheres (Diameter range 
from 1.00-2.49 μm, Catalog#SS04N, Bangs Laboratories Inc. USA) in RPMI-1640 
media without heat-inactivated fetal bovine serum (FBS, HyClone, USA) at 37ºC for 
1 hour. The other was to incubate bone marrow cells of P2 (M3, n=4) with 100 μg/ml 
of silica microspheres in RPMI-1640 media and 5% of FBS at 37ºC for 4.5 hours. In 
the latter two methods, bone marrow cells at 1×106 cells/ml were mixed with silica 
microspheres within a 15ml conical tube, and were shaken every 20 minutes. 
Subsequently, the cells were centrifuged at 300 ×g for 30 minutes at room temperature 
and suspended in 4 ml of Phosphate-buffered saline (PBS), as well as were laid onto 3 
ml of Ficoll-Paque™ PLUS (GE Healthcare, UK). Then interlayer cells were 
collected from the above mixture after centrifugation, were washed with 6 ml of PBS 
twice, and were cultured in CM at 1×104 cells/cm2 for continuous propagation. 
To remove the small amount of remaining hematopoietic cells after silica depletion, 
both M2 and M3 were negatively selected at P3 with a Lineage Cell Depletion Kit 
(Catalog# 130-090-858, Miltenyi Biotec Inc., Germany) following the manufacturer’s 
instructions. The negatively selected cells were then seeded in CM at 1×104 cells/cm2. 
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Upon reaching confluence, the cells were detached as above described. After P5, cells 
were seeded at 5×103 cells/cm2 and attained confluence around 3-4 days. Cell 
numbers were counted with 0.4% Trypan blue and recorded at every passage since P3. 
 
3.2.3 Detection of surface molecules of mMSC 
 
To determine whether these mMSC subpopulations express ‘so called’ stem 
cells-related molecule combinations, the surface molecular profiles of M1, M2, M3 
and M3 were supervised by immunofluorescent staining and flow cytometric analysis 
at every other passage number after P2. Briefly, 2×105 Cells were suspended in 10 μl 
of PBS and were incubated with rat anti-mouse CD16/CD32 (Clone 2.4G2, mouse 
FcR blocking Reagent) antibody at 4ºC for 5 minutes, followed by the addition of 
fluorescence conjugated monoclonal antibodies of Sca-1 (Clone E13-161.7, Catalog# 
553335), CD11b (Clone M1/70.15.11.5, Catalog# 130-081-201, Miltenyi Biotec), 
CD29 (Clone Ha2/5, Catalog# 555005), CD34 (Clone RAM34, Catalog# 11-0341), 
CD44 (Clone IM7, Catalog# 11-0441), CD45 (Clone 30F11, Catalog# 130-091-609, 
Miltenyi Biotec), CD73 (Clone TY/23, Catalog# 550741), CD90 (Clone 53.2.1, 
Catalog# 553003), CD105 (Clone MJ7/18, Catalog# 12-1051), CD117 (Clone 3C1, 
Catalog# 130-091-730, Miltenyi Biotec) respectively at 4ºC for 30 minutes. Cells 
were then washed with PBS once and fixed in 1% paraformaldehyde for analysis by 
using the CyAnTM ADP Analyzer (Beckman Coulter, USA) and Summit v4.3 software. 
For each antibody analysis, a minimum of 104 of cells was sorted. 
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3.2.4 Colony-forming units assay of mMSC 
 
M1 cells at P8 (M1P8), M2 cells at P8 (M2P8), M3 cells at P8 (M3P8) and M2 cells 
at P39 (M2P39) were seeded into 6-well plates at 10 cells/cm2, 50 cells/cm2 and 100 
cells/cm2 in duplicates. Fresh culture media was replaced every 3-4 days. On day 10, 
cells were stained with 0.25% crystal violet for 10 minutes. After photos were taken 
with a digital camera (Olympus, Japan) and photomicrographs were taken under an 
inverted fluorescence microscope (Olympus IX70, Japan), the dye was extracted with 
1 ml of 10% acetic acid per well. When the color was uniform, every 200 μl aliquot 
was transferred into each well of a 96-well flat bottom plate and the absorbance was 
read at 600 nm using the TECAN INFINITE M200 microplate reader (Tecan Group 
Ltd., Austria). 
 
3.2.5 Tri-lineage differentiation of mMSC 
 
Osteogenic differentiation. M1 at P9, M2 and M3 at P10, M2 at P32 (abbreviated as 
M1P9, M2P10, M3P10 and M2P32 respectively) were induced in Dulbecco’s 
Minimum Essential medium (DMEM) containing 10% FBS, 10 mM Sodium 
β-Glycerophosphate, 50 μg/ml Ascorbate-2-phosphate, 10-8 M Dexamethasone and 
1% PS for 28 days. During differentiation, mMSC were separately cultured in T75 
flasks for flow cytometric analysis, and in 6-well culture plates (2×103 cells/cm2) for 
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quantitative and qualitative testing. Cells were cultured in CM as controls. On day 14 
and day 28 of osteogenic inducement in 6-well plates, cells were ruptured in an 
extraction buffer (1.5 M Tris buffer, pH=9, with 1 mM MgCl2 containing 1% Triton 
X-100 [Bio-Rad]) for alkaline phosphatase (ALP) quantitative assay [Toh 2007]. Cell 
suspensions were sonicated to dissociate the extracellular matrix (ECM) and liberate 
membranous ALP. Specific ALP activity was evaluated by the release of 
p-nitrophenol from p-nitrophenylphosphate, and the absorbance was measured at 405 
nm using the TECAN INFINITE M200 microplate reader, assuming that 1 A405 = 64 
nmol of product. Total protein concentration in a well was determined using the 
Pierce BCA protein assay kit (Pierce Chemicals, USA). In addition, on day 28 of 
osteogenic inducement, cells were fixed with 1% paraformaldehyde at room 
temperature for 30 minutes and stained with alizarin red (pH=4.1) for 30 seconds, 
then were washed with water completely. Photos were taken under the Olympus 
inverted microscope after the staining finished. 
To compare the osteogenic potential of different mMSC subpopulations in vitro, cells 
were harvested from T75 flasks after 28-day osteogenic inducement and were fixed in 
1% paraformaldehyde at room temperature for 10 minutes, followed by being washed 
with PBS once, prior to incubation in perm buffer [PBS containing 1% FBS, 10% 
rabbit serum, 5mM EDTA (6381-92-6, Duchefa Biochemie, Netherlands) and 0.1% 
Saponin] at room temperature for 30 minutes, incubation with anti-mouse 
CD16/CD32 antibody at 4ºC for 5 minutes, and Goat anti-mouse osteocalcin (OC) 
polyclonal antibody (BT-592, 1:250, Biomedical Technologies Inc. USA) 
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[Olmsted-Davis, 2003] at 4ºC for 45 minutes. Cells were then washed with perm 
buffer once and incubated with Cy5 Rabbit anti-goat IgG (81-1616, 1:500, Zymed 
Laboratories, Invitrogen) at 4ºC for 15 minutes. Cells were subsequently washed with 
PBS and fixed in 1% paraformaldehyde for analysis as above described. A minimum 
of 104 of each type of cells was sorted. 
Chondrogenic differentiation. M1P9, M2P10, M3P10 and M2P32 were induced in 
DMEM containing 1% ITS Premix (BD Biosciences), 10 ng/ml TGF-β1 (R&D 
Systems, USA), 50 μg/ml Ascorbate-2-phosphate, 10-7 M Dexamethasone, 40 µg/ml 
L-proline, 1% sodium pyruvate, 1% nonessential amino acids (Invitrogen), 1% 
Glutamax (Invitrogen) and 1% PS at 2.5×105 cells/tube in 3-D pellet culture for 28 
days. Pellets cultured in media without TGF-β1 served as the controls. The 
differentiation was analyzed by toluidine blue staining [Liu 2006] and sulfated 
glycosaminoglycan (s-GAG) quantitation using Biocolor Blyscan Glycosaminoglycan 
Assay kits (Biocolor Ltd, Ireland) [Toh 2005]. In brief, for toluidine blue staining, 
those pellets were fixed in 4% paraformaldehyde, processed, embedded in paraffin, 
sectioned at 5 μm in thickness, rehydrated, stained in 1% toluidine blue at 37ºC for 10 
minutes, counterstained in 100% isopropanol for 1 minute, dehydrated, mounted in 
Xam (Xam : Xylene = 1 : 1) and dried overnight. Photos were taken by the Olympus 
inverted microscope. To measure the total s-GAG deposited by chondrogenic cells, 
cell pellets were digested with 200 μl papain digestion buffer (125 μg/ml in sterile 
PBS, pH=6.0 with 5 mM cysteine hydrochloride and 5 mM Na2 EDTA) for 18 hours 
at 60ºC before following the instruction of the Blyscan Sulfated Glycosaminoglycan 
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Assay kit. The color of s-GAG content was measured at 630 nm by using the TECAN 
INFINITE M200 microplate reader, and normalized to the total DNA content which 
was stained with Hoechst 33258 and was detected by the same microplate reader. The 
amount of s-GAG was graphed against the standard curve of bovine trachea 
chondroitin sulfate as the manufacturer instructed, while the amount of DNA was 
calculated upon the standard curve of Calf thymus DNA. 
Adipogenic differentiation. M1P9, M2P10, M3P10 and M2P32 were induced in 
DMEM containing 10% FBS, 5 μg/ml Insulin, 60 μM Indomethacin, 50 μM 
3-Isobutyl-1-methylxanthine, 10-7 M Dexamethasone, and 1% PS at 2×105 cells/well 
within 6-well plates for 7-10 days. Cells were fixed and stained with 0.36% of 
oil-red-O for 1 hour. After being imaged, the dye was extracted by 100% isopropanol 
at room temperature for 10 minutes. Every 200 μl of dye extraction was transferred 
into one well of a 96-well flat bottom plate and the absorbance was read at 500 nm 
using the microplate reader. 
 
3.2.6 Karyotyping of mMSC chromosomes 
 
Metaphase spreads preparation. Subconfluent M2 at P25, P35, P45 and P55 were 
incubated in Colcemid (0.25 μg/ml, Invitrogen) at 37ºC for 6 hours and detached. The 
cell pellet was suspended in hypotonic KCl (0.075M) at 37ºC for 15 minutes and was 
fixed in chilled modified Carnoy’s fixative (glacial acetic acid: absolute methanol = 1: 
3). Metaphase spreads were prepared by dripping the fixed cell suspension from 20 
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cm above the pre-cleaned slides (Fisher Scientific Inc., USA) and drying on a 65ºC 
hotplate. The short hypertonic treatment time and low height of dripping cell 
suspension were meant to prevent the formation of broken metaphases. The slides 
were aged at room temperature for 10 days before G-banding. 
Giemsa banding. Slides with murine metaphase spreads were immersed for 30 
seconds in a coplin jar containing 2.5% trypsin/0.9% NaCl mixture, followed by 
washing with 0.9% NaCl solution twice. The slides were then stained with Gurr's 
Giesma working solution for 5 minutes, followed by washing in Gurr's 6.8 buffer 
(Invitrogen) twice. The slides were air-dried and coverslipped with Cytoseal 60 
(Cole-parmer, USA). Metaphase analysis was performed with a Zeiss Axioplan 
microscope (Carl Zeiss GmbH, Germany). 
 
3.2.7 In vivo osteogenic potential comparison of mMSC 
After anesthesia, BALB/c mice were injected subcutaneously with 5×106 of M1P14 
and M2P14 in 200 μl of PBS in both sides of the abdominal wall. The successful 
injection showed protrusion of skin at the injection sites which were labeled with 
gentian violet. At twelve-day post-implantation, the whole skin around the injection 
area were cut, fixed and embedded in OCT compound cryo-media [Jung, Leica 
Microsystems, Germany]. Specimens were sectioned at 6 μm in thickness. The slides 
were permeablized and blocked in perm buffer (the same as that for flow cytometric 
analysis) at 37ºC for 30 minutes. The slides were stained with primary antibodies 
[MHC-Ib (Clone 2G5, diluted at 1:12.5), and antibodies to osteogenic markers, such 
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as anti-mouse ALP antibody (Clone B4-78, bone and liver specific, DSHB, USA; 
diluted to 5 μg/ml), anti-mouse osteopontin (OPN) antibody (Clone MPIIIB10, DSHB, 
diluted to 5 μg/ml), Goat anti-mouse OC antibody (diluted at 1:50)] in perm buffer at 
room temperature for 1 hour and subsequently with secondary antibody [Qdot655 
Goat anti-mouse IgG (diluted at 1:200) for ALP and OPN detection, Cy5 Rabbit 
anti-goat IgG (diluted at 1:100) for OC detection] at room temperature for 1 hour. 
Slides were mounted in VECTASHIELD Mounting Medium (H-1200, Vector 
Laboratories, USA) and observed under fluorescence microscope. Besides fluorescent 
staining, some slides were performed hematoxylin and eosin (H&E) staining to show 
tissue morphology as well as alizarin red staining to investigate the existence of 
mineral deposition. 
When those cryosection slides were performed the H&E staining, they were immersed 
in PBS at room temperature for 4 minutes × 3 times, then went through Gill No.3 
hematoxylin, Scott’s tape water, eosin, 5 minutes per step of staining. For those 
stained with alizarin red, the slides were stained with alizarin red at room temperature 
for 10 seconds after going through PBS. All those stained slides were dehydrated, 
mounted with Xam and dried overnight. Photos were taken by the Olympus inverted 
microscope. 
 
3.3 IMMUNOLOGICAL TESTING OF MSC IN VITRO 
 
The in vitro immunological testing of mMSC at serial passage numbers includes the 
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detection of surface MHC molecules on mMSC, the investigations of immunogenicity 
and immunoinhibition of mMSC, and the exploration of mechanisms behind these 
immune properties of mMSC. Based on the results of section 7.1, M2 was selected to 
be the appropriate mMSC subpopulation for further immunological testing. 
Additionally, in this section of testing, spleen mononuclear cells (MNC) of C57BL/6 
and BALB/c mice were obtained by mechanical mince, 100 μm-pore size mesh 
filtration and Ficoll-Paque™ PLUS fractionation at 300 ×g for 20 minutes. 
 
3.3.1 Detection of MHC molecules on mMSC at serial passage numbers 
 
Mouse MSC (2×105 cells) at serial passage numbers were suspended in 10 μl of PBS 
and were incubated with rat anti-mouse FcR antibody at 4ºC for 5 minutes, followed 
by the addition of fluorescence conjugated monoclonal antibodies of MHC-Ib (FITC 
conjugated, H-2Kb, Clone 28-14-8, Catalog# 11-5999) and MHC-II (FITC conjugated, 
Clone NIMR-4, Catalog# 11-5322) respectively at 4ºC for 30 minutes. Cells were then 
washed with PBS once and fixed in 1% paraformaldehyde for analysis by using the 
CyAnTM ADP Analyzer and Summit v4.3 software. For each antibody analysis, a 
minimum of 104 of cells was sorted. 
 
3.3.2 Coculture of allogeneic mMSC at serial passage numbers and naive spleen 
mononuclear cells 
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To investigate whether allogeneic mMSC is immunogenic, inactivated mMSC were 
incubated with BALB/c MNC and the proliferation of MNC was observed. To 
confirm complete inactivation of mMSC, titrated mitomycin C (MMC) was used and 
the growth curve of mMSC after 3 days of inactivation was drafted (Figure 4). Based 
on the curve, the optimal concentration of MMC, 25μg/ml, was utilized for later 
experiment. Briefly, M2 at P5, P7, P8, P10, P12, P14, and C57BL/6 MNC were 
inactivated by 25 μg/ml of MMC in darkness at 37ºC for 20 minutes and washed 
completely with PBS × 3 times, prior to being suspended in lymphocyte culture 
medium (RPMI-1640 containing 5% FBS, 50 μM 2-mercaptoethanol and 1% PS). 
C57BL/6 MNC and BALB/c MNC were suspended at 1×106 cells/ml, while M2 at 
serial passage numbers were suspended at 105 cells/ml. Ten thousand M2 and 105 of 
C57BL/6 MNC (positive control) were co-cultured with 105 of BALB/c MNC in 
triplicates within a 96-well U bottom plate in 0.2 ml/well of medium for 6 days. The 
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same number of BALB/c MNC in culture without M2 was utilized as negative control. 
Sixteen hours before harvesting, tritium-labeled thymidine (0.5 μCi/well, Bio-Rad 
Laboratories, USA) was added into the each well. Counts per minute (CPM) of 
tritium was recorded with a liquid scintillation counter (TopCount NXT, PerkinElmer, 
USA). 
 
3.3.3 Incubation of allogeneic mMSC at serial passage numbers and one-way mixed 
lymphocyte culture 
 
To determine whether mMSC have the immuno-inhibitory effect on proliferating 
MNC upon allogeneic antigen stimulation, one-way mixed lymphocyte culture (MLC) 
was used as a testing system. Briefly, 105 of BALB/c MNC and 105 of inactivated 
C57BL/6 MNC were added into the mMSC wells pre-seeded with 104 of M2 at 
various serial passage numbers one day before co-culture. The co-culture of the same 
number of BALB/c MNC and inactivated C57BL/6 MNC in the wells without M2 
was utilized as positive control. As above described, the numbers of proliferating 
BALB/c MNC were analyzed after 6 days by the incorporation of tritium-labeled 
thymidine. The CPM of BALB/c MNC in experimental groups (CPMexp) can be 
calculated by deducting CPM of non-BALB/c MNC from CPM of the total cells 
within co-culture. The inhibition of BALB/c MNC proliferation (%) was calculated as 
(CPMcontrol-CPMexp)×100/CPMcontrol.  
 
 - 63 -
MATERIALS AND METHODS                                                            H. LIU 
3.3.4 Incubation of allogeneic mMSC at serial passage numbers, Concanavalin A 
and spleen mononuclear cells 
 
To confirm the inhibitory effect of mMSC on proliferating MNC, mitogen induced 
MNC proliferation was used as the other testing system. Similar to the above testing, 
105 of BALB/c MNC and 3 μg/ml of concanavalin A (Con A) were added into mMSC 
wells which were pre-seeded with 104 of M2 at various serial passage numbers 1 day 
before co-culture. The numbers of proliferating BALB/c MNC were analyzed after 48 
hours by 8-hour incorporation of tritium-labeled thymidine. The co-culture of 
BALB/c MNC and Con A in the wells without mMSC was utilized as positive control. 
The inhibition of BALB/c MNC proliferation (%) was calculated with the same 
formula as above. 
 
3.3.5 Testing the effect of mMSC secretion on allogeneic MNC proliferation 
 
To tell whether MSC-MNC contact or soluble molecules of mMSC performs a more 
important role in the inhibition of mMSC on allogeneic MNC proliferation, a 
transwell system and a supernatant system were hired for this investigation. In brief, 
titrated numbers of M2 at P14 (2×103, 1×104 and 5×104 respectively) were seeded 
into 8-well strip transwell inserts 1 day before being transferred onto a 96-well flat 
bottom plate of MLC. The numbers of proliferating BALB/c MNC were analyzed 
after 6 days as previously described. For supernatant testing, supernatant of 104 M2 at 
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P14 in 96-well flat bottom plates was collected after 5-day sole culture. Different 
volumes of M2 supernatant (160 μl, 80 μl and 40 μl) were added into the wells of 
MLC. The volume of each well was topped up to 200 μl with culture media. The 
MLC wells without M2 inserts or M2 supernatant served as positive control. The sole 
BALB/c MNC in culture was utilized as negative control. To compare with the effect 
of mMSC by direct contact, the co-culture of BALB/c MNC, C57BL/6 MNC and M2 
was also tested on the same plate. The numbers of proliferating BALB/c MNC were 
analyzed after 6 days as previously described. 
 
3.3.6 Testing of soluble molecules in mMSC supernatant 
 
To identify the soluble molecules mediating MSC-dependent immuno-inhibition, the 
supernatant was collected from MSC sole culture and the co-culture of MLC and 
MSC with/without inserts separation. The components in supernatant were 
determined according to the detection kits. Briefly, one million of BALB/c MNC and 
1×106 of inactivated C57BL/6 MNC were added into the 24-well plates which were 
pre-seeded with 1×105 M2 at P8 or were pre-loaded the prepared inserts containing 
1×105 M2 at P8/insert 1 day ago. To find out the effect of TGF-β and IL-10 on the 
immuno-inhibitory properties of mMSC, 10 μg/ml of TGF-β (Clone 1D11, Catalog # 
MAB1835, R&D Systems) and IL-10 (Clone JESS-2A5, Catalog # 16-7102) blocking 
antibodies were added into the co-culture of MLC and MSC. The total volume of 
media was 1ml/well in 24-well plates and 200μl/well in 96-well plates. Five days later, 
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the CPM of the proliferating cells in the 96-well plates was measured, while the 
media in all wells of the 24-well plates were collected and centrifuged. The 
supernatants were kept for later TGF-β bioassay and stored at -80ºC for multiplex 
testing. Additionally, supernatant from sole mMSC culture was also collected as 
control.  
Harvested supernatant were thawed and analyzed with Procarta mouse cytokine assay 
kits (Panomics, USA) following the manufacturer’s instruction. The kits were 
designed for examining IL-3, IL-4, IL-6, IL-10, IL-13, IL-17 and IFN-γ in a single 
sample, as well as the total TGF-β in a separate sample. Briefly, premixed antibody 
beads were added into a pre-wet filter plate and were washed. Then 50 μl of samples, 
25 μl of premixed detection antibodies and 50 μl of streptavidin-Phycoerythrin were 
added into the plate and incubated for 30 minutes in sequence. Lastly, 120 μl/well of 
reading buffer were added and read by a Luminex 100 plate reader (Qiagen, USA). 
For TGF-β assay, cell culture supernatant were activated with 1N HCl and neutralized 
with 1.2N NaOH/0.5M HEPES as instructed. 
 
3.3.7 TGF-β bioassay 
 
To confirm the effect of active form of TGF-β in the supernatant of mMSC, the 
inhibition of active TGF-β on Mv1Lu cell proliferation was examined [Mazzieri 
2000]. One hundred microlitre of freshly harvested supernatant were added into 
4×104/well of Mv1Lu cells (CCL-64, ATCC) respectively in 96-well plates and 
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cultured at 37ºC for 24 hours. Twenty microlitres of MTS was added into each well of 
the coculture 3 hours before measurement. The optical density was read at 490nm 
with the microplate reader. 
 
3.3.8 Analysis of TGF-β and IL-10 secreting cells in coculture of mMSC and MLC 
 
To further track the origin of TGF-β and IL-10 secretion, the proportion of TGF-β and 
IL-10 secreting cells in the co-culture of MLC and MSC were analyzed. Concisely, 
one million of BALB/c MNC and 1×106 of inactivated C57BL/6 MNC were added 
into a 24-well plate with or without 1×105 M2 at P14. On day 5 of the co-culture, the 
suspending cells and the attached cells of the same well were harvested. The detached 
cells were stained with MHC-Ib (FITC conjugated) and CD3 (Pacific blue conjugated,  
Clone 17A2, Catalog # 100214, BioLegend, USA) monoclonal antibodies at 4ºC for 
30 minutes, while suspending cells from the wells of MLC with or without mMSC 
were stained with MHC-Ib, CD4 (Pacific blue conjugated, Clone rm4-5, Catalog # 
558107) and CD8 (R-phycoerythrin conjugated, Clone 53-6.7, Catalog # 553033) 
monoclonal antibodies at 4 ºC for 30 minutes. Then cells were fixed in 4% 
paraformaldehyde at room temperature for 5 minutes and incubated in perm buffer at 
room temperature for 30 minutes, followed by incubation with anti-mouse FcR 
antibody at 4ºC for 5 minutes and TGF-β or IL-10 blocking antibodies at 4ºC for 45 
minutes. Then cells were incubated with allophycocyanin (APC) conjugated rat 
anti-mouse IgG secondary antibody (Catalog # 550874) or APC conjugated goat 
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anti-rat IgG1 secondary antibody (Catalog # 405407, BioLegend) accordingly at 4ºC 
for 15 minutes. Cells were then washed with PBS once and fixed in 1% 
paraformaldehyde for analysis by using the CyAnTM ADP Analyzer and the Summit 
v4.3 software. For each antibody analysis, a minimum of 104 cells were sorted.  
 
3.4 IMMUNOLOGICAL TESTING OF MSC IN VIVO 
 
The in vivo immunological testing of mMSC needs to establish an animal model for 
allo-immunological testing at first. To achieve this purpose, delayed-type 
hypersensitivity of mouse footpads was selected. This testing measures the mouse 
footpad swelling challenged by the same priming antigens, so as to evaluate the 
antigen-specific, MHC-restricted immune responses which are mediated by Th1 cells 
and CTL [Barrington-Leigh 1984, Cher 1987, Luo 2007]. Based on the results of 
section 7.2, M2 at P8 and M2 at P14 were selected as representatives of an early and a 
late passage numbers of mMSC respectively to perform the testing. 
 
3.4.1 Delayed-type hypersensitivity reaction of allogeneic mMSC at different 
passage numbers 
 
To confirm the successful establishment of delayed-type hypersensitivity responses in 
mice, positive and negative controls were tested first. After anesthesia, BALB/c mice 
were injected subcutaneously with 5×106 of C57BL/6 MNC in 200 μl of PBS on both 
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sides of the abdominal wall (priming). At day 
10 post-implantation, 5×106 of inactivated 
C57BL/6 MNC in 25 μl of PBS were injected 
into one hind footpad of the BALB/c recipient 
subcutaneously (Challenge). Another 25 μl of 
PBS were injected into the other hind footpad 
subcutaneously as an internal negative control. 
The baseline of footpad thickness was 
measured before the challenge. The footpad 
thickness was measured at 24 hours and 48 
hours after challenge with a micrometer 
(Mitutoyo, Japan) [Luo 2007, Yamashita 2009] (Figure 5). The footpad swelling was 
calculated by subtracting the thickness of the footpad baseline from the thickness of 
the footpad at testing time points. For the negative control of experimental group, 
there was no C57BL/6 MNC injection at priming. For the experimental groups, 5×106 
of M2 at P8 or M2 at P14 instead of C57BL/6 MNC were injected subcutaneously 
into BALB/c mice at priming. All other steps were the same as positive controls. 
Figure 5 Measurement diagram of 
BALB/c footpad thickness. 
To confirm the accuracy of footpad swelling responses, the lymphocyte infiltration in 
footpads were observed under microscope after H&E staining. In brief, footpads of 
BALB/c mice were harvested 48 hours after challenge and fixed with 4% 
paraformaldehyde. Then they were decalcified in 10% acetic acid for 2 weeks, 
embedded in paraffin and sectioned at 5 μm in thickness. The H&E staining procedure 
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was the same as part 7.1.7 described. 
 
3.4.2 Testing of the inhibitory effect of allogeneic mMSC at different passage 
numbers on recalled immune responses 
 
To verify the inhibitory effect of allogeneic mMSC on recalled immune responses, the 
mMSC of the same passage number as that for priming were injected subcutaneously 
in abdominal wall with the challenge of C57BL/6 MNC at footpads. Approximate 
1×106 of M2 at P8 or M2 at P14 in 180μl of PBS were injected into BALB/c 
recipients accordingly. The footpad swelling were measured and evaluated as above. 
The footpads were harvested 48 hours after challenge, and H&E staining were 
performed on footpad sections.  
 
3.4.3 Testing of the inhibitory effect of allogeneic mMSC secretion at a late passage 
number on recalled immune responses 
 
To test the inhibitory effect of mMSC secretion and compare its magnitude with that 
of mMSC through direct contact with in vivo milieu on recalled immune responses, a 
diffusion chamber system, which separates mMSC from environment but no blocking 
of nutrient communication, was used. Different from the procedure of part 7.3.2, 
approximate 1×106 of M2 at P8 or M2 at P14 in 180μl of PBS were injected into 
diffusion chambers (Figure 6A) which consisted of Plexiglas® Rings with 0.59 mm 
 - 70 -
MATERIALS AND METHODS                                                            H. LIU 
hole (Catalog # PR0001401, Millipore, USA) and MF-Millipore™ Membrane Filters 
(Catalog # HAWP01300, Millipore) glued by chamber specific Cement (Catalog # 
SD1M057E04, Millipore). These M2-loading diffusion chambers were inserted into 
abdominal wall with challenge of C57BL/6 MNC at footpads. The footpad swelling 
were measured and evaluated as part 7.3.1.  
To confirm the separation efficacy of the diffusion chambers, M2 were labeled with 
PKH26 (Catalog # MINI26) following the instruction of supplier before implantation. 
Briefly, 1 ml of 1×107 suspending mMSC were mixed with 1 ml of PKH26 at 2×final 
concentration completely and incubated at room temperature for 5 minutes. The 
further staining reaction was terminated by adding 2 ml of cold FBS and incubated for 
1 minute. Then the extra dye was washed off with complete media for 3 times. The 
final staining concentration of PKH26 was determined by serial titration. Results 
showed that 8 μM of PKH26 was the optimal among 6 different concentrations used 
as it provides sufficient brightness and time period for observation (Figure 7). The 
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efficacy of chamber separation was verified by separating PKH26 labeled MSC and 
local graft tissues counterstained with FITC conjugated MHC-Id antibody (Clone 
34-1-2S, Figure 6B). 
 
 
3.4.4 Testing of the role of TGF-β and IL-10 in the inhibitory effect of allogeneic 
mMSC 
 
To determine whether TGF-β and IL-10 contributed to the immuno-inhibitory effect 
of the MSC supernatant in vivo, blocking antibodies were added to MSC at P14. To 
control the release of blocking antibodies locally, a resorbable and self-assembling 
nanoscale hydrogel (PuraMatrix, 3DM Inc., USA) was used to embed mMSC (1×106 
in 180μl of PBS) and antibodies (100μg/ml). The degradation of 200μl of hydrogel at 
different concentrations (0.25%, 0.5% and 1%), which were mixed with 1×106 of 
PKH26-labeled mMSC, was observed in vitro for up to 35 days. Results showed that 
0.5% of hydrogel were more easily controllable than 0.25% and 1% of hydrogel in 
terms of their gelling speed and morphology (Figure 7). In vitro, 0.5% of hydrogel 
started to degrade around 10 days in culture, assessed by gel morphology change and 
gel chips production under microscope. However, the morphology of 0.25% of gel 
begun to change around 3 days, while the morphology of 1% of gel was maintained 
up to 35 days under the same conditions. According to the hydrogel supplier, 200μl of 
0.5% hydrogel could be gradually absorbed around 1 week after injection in vivo. 
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Based on these optimization, 0.5% of hydrogel was selected for later experiment. 
Then the mMSC-antibody-hydrogel containing diffusion chambers were inserted into 
BALB/c abdominal wall subcutaneously with challenge of C57BL/6 MNC at footpads. 
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The footpad swelling were measured and evaluated as part 7.3.1 demonstrated.  
 
3.4.5 Analysis of immune cell components in blood and spleens 
To find out the immune cell types affected by mMSC, blood and spleen MNC from 
BALB/c mice of all control and experimental groups were analyzed. Forty eight hours 
post-challenge, BALB/c spleen and blood MNC were blocked with rat anti-mouse 
FcR antibody at 4ºC for 5 minutes, and were stained with MHC-Id, CD4, CD8 and 
CD3 (APC conjugated, Clone 145-2C11, Catalog # 130-092-977) antibodies at 4ºC 
for 30 minutes. Subsequently, the cells were washed with PBS and fixed in 1% 
paraformaldehyde. The results were analyzed with the CyAnTM ADP Analyzer and 
Summit v4.3. 
 
3.4.6 Analysis of immune molecules in serum 
To explore the alteration of immune molecules under the influence of allogeneic 
mMSC in vivo, blood was harvested from all BALB/c mice for further analysis. After 
collection, the blood was left at room temperature for at least 30 minutes and 
centrifuged at 300 ×g for 5 minutes, and then the serum was collected and stored at 
-80ºC for multiplex analysis. The tested cytokine types and the testing procedure were 
similar to those demonstrated in part 7.2.6. 
 
3.5 STATISTICAL ANALYSIS 
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Quantitative results were analyzed by independent-samples t test or one-way ANOVA 
(SPSS 13.0 for Windows, SPSS Inc., USA). A value of P< 0.05 was considered 
significantly different, and a value of P< 0.01 was considered very significantly 
different. 
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4.0 RESULTS 
 
In this study, the identity and biology of mouse MSC derived by a new method have 
been fully examined. Excluding the influence of variable culture environment, both in 
vitro and in vivo immune properties of the selected MSC subpopulation at various 
passage numbers have been further investigated. 
 
4.1 THE IDENTITY OF MSC 
 
As defined by the International Society for Cellular Therapy [Dominici 2006], MSC 
should be free of hematopoietic cell contamination, express a group of suggested 
surface molecules, and self-renew. Most importantly, they could differentiate into 
osteo-, chondro- and adipo- lineage cells. Therefore, the newly derived MSC 
subpopulations had been identified according to this guideline, followed by the 
therapy-related biological tests.  
 
4.1.1 Bone marrow stromal cells were free of hematopoietic cell contamination 
 
As observed, attached primary mouse bone marrow cells reached 100% of confluence 
around 5-7 days after seeding. Then they were detached by trypsin-digestion for 2 
minutes and split at 1:2 for next 5 generations. The detached cells at P6 were found to 
be Lineage-, CD11b-, CD45- and CD117- with 99% purity (Figure 8A). To get highly 
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pure hematopoietic cells-free MSC at an earlier passage number, silica depletion was 
performed. Phagocytosis of silica by monocytes and macrophages increases their 
mass and hence leading to their sedimentation after Ficoll-Hypaque centrifugation. 
This enables the removal of contaminating monocytes and macrophages. Results 
showed that the contamination of bone marrow CD11b+ cells decreased from 
81.86±10.96% (Mean ± SE) at P2 to 13.96±3.03% at P3 after 4.5-hour incubation 
with silica, while to 46.11±10.54% after 1 hour incubation at P3. Subsequently, these 
cells were then subjected to negative selection at P3. Upon reaching confluence at P5, 
the contamination by hematopoietic cells (including Lineage+, CD45+, CD11b+ and 
CD117+ cells) was reduced to within 1% (Figure 8B and C). 
 
4.1.2 Bone marrow stromal cells displayed MSC phenotype 
 
All three bone marrow stromal cell populations displayed different surface molecule 
profiles. When bone marrow cells were not incubated with silica (named as M1, 
Figure 8A), they showed strong expression of Sca1, CD90 and CD105, as well as low 
expression of CD34 and CD73 at P6. After 1-hour incubation with silica followed by 
Ficoll fractionation, bone marrow cells (named as M2, Figure 8B) at P5 were negative 
for expression of CD90 and CD105, but were positive for expression of CD34, Sca1 
and CD73. At an identical passage number, bone marrow cells incubated with silica 
for 4.5 hours (named as M3, Figure 8C) displayed strong expression of Sca1 and 
CD105, but negative expression of CD34, CD73 and CD90. During prolonged culture 
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of M2, the expression of Sca-1, CD34, CD73, CD90 and CD105 was tracked every 
even passage numbers. The data show that the expression of CD34 completely 
disappeared by P36 (Figure 8F) and that of Sca1 completely disappeared by P40 
(<1%, data not shown). However, M2 never expressed CD90 and CD105 but kept 
similar level expression of CD73 until the last passage (Figure 8B, D, E and F). 
Regardless of passage number or treatment with silica, strong and stable expression of 
CD29 and CD44 were observed in all cells (Figure 8). 
 
4.1.3 Bone marrow stromal cells displayed tri-lineage differentiation ability 
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Although the derived individual bone marrow stromal cell populations displayed 
universal and stable expression of certain MSC surface molecule combinations, they 
are heterogeneous in terms of morphology; with mixture of predominantly 
spindle-shaped fibroblastic cells and small rounded cells, together with a minority of 
giant flat cells. M1P9, M2P10 and M3P10 were similar (Figure 9A, E and I) in size. 
The morphology and the size of M2 were maintained up to P39 (Figure 9M).  
All derived bone marrow stromal cell populations showed tri-lineage differentiation 
potential on day 28 of osteogenesis (Figure 9C, G, K and O) and chondrogenesis 
(Figure 9B, F, J and N), as well as on day 10 of adipogenesis (Figure 9D, H, L and P) 
after induction. However, their differentiation potential were varied in each population. 
M1 osteogenic nodules were small and disperse, whereas M2P10, M3P10 and M2P32 
osteogenic nodules were dense. When observed macroscopically, a higher percentage 
of M2 displayed bone matrix deposit (Figure 10A and B) as compared to M3 (Figure 
10C). Under microscopic observation (Figure 9), there were more chondrogenic cells 
of typical morphology with dense cartilaginous matrix, and a much lower percentage 
of mature adipocytes displayed by M1P9, M2P10 and M2P32 as compared to M3P10. 
The lipid droplets in M2P32 had a small and immature morphology. 
To further distinguish the differentiation potential of M2 and M3, quantitative assays 
of osteogenesis, chondrogenesis and adipogenesis were performed on M2P10, M2P32 
and M3P10. On day 28 of osteogenic induction, there was much more intracellular 
OC synthesis in M2P10 compared to M3P10 (Figure 10G). The ALP activities of both 
M2P10 and M2P32 decreased with extension of osteogenic induction (Figure 10E). 
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Although a low level of ALP activity was detected in M3P10 at the starting point of 
differentiation, it gradually increased up to day 28 and then decreased thereafter. On 
day 28 of differentiation, the ALP activity of M3 was significantly higher than that of 
both M2P10 and M2P32 (p<0.01). After an extension of 14 days and 28 days of 
osteogenic differentiation, the ALP activity of M3 remained significantly higher than 
that of M2 (p<0.01). Interestingly, the expression of CD73 was maintained during the 
whole osteo-inducing period of M2P10, which was also manifested in M3P10 by the 
same osteo-inducing method (Figure 10H). Upon oil red extraction from adipogenic 
cells of M2 and M3, M3P10 showed significantly higher absorbance than M2P10 and 
M2P32 (p<0.01) (Figure 10D). In chondrogenic differentiation, M2 demonstrated 
significantly higher level of s-GAG/DNA when compared to the control media (*, 
p<0.05; **, p<0.01), while M3 did not (Figure 10F). Chondro-differentiated M2 also 
secreted significantly higher levels of s-GAG than chondro-differentiated M3 in a 
single cell level (p<0.05). Upon comparison of M2P10 and M2P32, the secretion of 
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4.1.4 Bone marrow stromal cells displayed rapid proliferation 
 
Based on colony-forming assay, both M2P8 and M2P39 displayed rapid proliferation. 
The colonies of M2 were dense and compact with clear boundaries, while M3P8 
colonies were less compact and more diffuse (Figure 11). Upon extraction of crystal 
violet dye, M2P39 showed the highest concentration of dye, while M3P8 showed the 
lowest. The difference between them was significant (*, p<0.05; **, p<0.01). 
As in previous studies, mouse MSC displayed a much slower growth rate compared to 
MSC isolated from other species. With our protocol, it took approximately 5-7 days to 
attain confluence in the first two passages at a split ratio of 1:2. Higher passage 
splitting ratio of mMSC caused a delay or stoppage of growth. After silica treatment, 
the time duration to attain confluence in the next 2 passages elongated from 5 to 16 
days. However at a seeding density of 5×103 cells/cm2, the proliferation rate sped up 
from the 5th passage onwards, with the time duration required to attain confluence 
shortened to 3-4 days. Additionally, although M2 and M3 could be cultured for a long 
period of time in vitro, M2 displayed a faster proliferation rate than M3 in an 
extended stage at the same seeding density (Figure 11), and could survive for more 
than 70 passages in vitro, which approximates to about 275 doublings. 
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4.1.5 Bone marrow stromal cells kept normal karyotype during long-term culture 
 
Although M2 kept fast growth speed during the long observation period, the maximal 
number of M2 in one T75 flask was constant from P17 to P34, with approximately 
6.48±1.71×106 cells (mean±SE). One extra day of culture did not significantly 
increase the cell number at confluence. By Giemsa banding, majority of M2 revealed 
normal diploid karyotype in cells from all tested passage numbers (Figure 12A). Less 
than 5% of cells were aneuploid (Figure 12B). There was no increase in frequency of 
aneuploid cells with increasing passages. Additionally, various euploid M2 were 
detected in different copy numbers, such as 3N, 4N and 5N. No cells with >5N ploidy 
were observed. Polyploidy cells were less than 8% of total cells at P25 and P35, while 
they increased up to approximate 20% of total cells at P45 and P55. 
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4.1.6 Selected bone marrow stromal cell subpopulation displayed normal biological 
function at local graft site 
 
Although M2 displayed significant advantages on the osteo- and chondro- 
differentiation as well as proliferation than M3 in vitro, M1 displayed similar high 
proliferative capacity and osteogenic potential as M2. To determine the most suitable 
cell source for further immunological studies, their biological activities were further 
investigated in vivo. By subcutaneous injection, the skin protuberance resulting from 
M1 subcutaneous injection disappeared after 12 days post-injection. By staining with 
MHC-Ib antibody, only a small group of M1 cell grafts were detected at injection sites 
of abdominal skin specimens (Figure 13A). In contrast to M1, the skin protuberance 
from M2 injection could be easily observed by naked eyes after 12 days. After cutting 
through the centre of the M2 protuberance, a white area resembling bone formation 
could be observed (Figure 13G). Upon cryosectioning and immunofluoresence 
staining, low levels of ALP could be detected in M1 graft specimens (Figure 13D), 
while low level of ALP as well as moderate levels of OPN and OC could be detected 
in M2 graft specimens (Figure 13J, K and L). With further Alizarin red staining, a few 
scattered areas with dark pink stains were observed in M2 graft specimens (Figure 
13I). By H&E staining, M2 graft area (Figure 13H) showed more abundant matrix 
and higher cell density than M1 graft area (Figure 13B). There were red blood cells 
filling in vessel-like tissue gaps in M2 graft area and lymphocytes infiltration could be 
observed in both M1 and M2 graft areas. 
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Based on above data, all three bone marrow stromal cell populations displayed MSC 
characteristics with tri-lineage differentiation potential, little hematopoietic cell 
contamination and a stable expression of a certain MSC molecule combination. 
Although they expressed different combination of surface molecules, they may 
represent different subpopulations of MSC. Particularly, M2 showed higher osteo- and 
chondro- differentiation potential and faster proliferation rate with normal karyotype, 
which may represent a better cell source for regenerative application than M1 and M3. 
Furthermore, M2 demonstrated normal bone matrix protein synthesis and secretion in 
vivo, as well as steady residence at subcutaneous injection sites up to 12 days 
post-implantation, providing a good tool for observing local reaction around grafts. 




4.2 THE IMMUNE PROPERTIES OF MSC ALTERED WITH EXTENDED 
CULTURE IN VITRO 
 
4.2.1 Low expression of MHC did not increase with extended culture 
 
To investigate the allo-immunogenicity with extended culture, the alteration of MHC 
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expression was first investigated. M2 had low expression of MHC-Ib and negative 
expression of MHC-II at P8 (Figure 14A). With continuous passage in vitro, the 
MHC-Ib expression on M2P14 did not increase as expected (Figure 14A), neither did 
MHC-II expression. Moreover, twelve days post-implantation, both P8 MSC and P14 
MSC loaded MHC-I as shown by immunofluorescence staining (Figure 14B). 
 
 
4.2.2 Allo-immune responses increased along extended culture 
 
With serial passage, MSC displayed distinct alteration of allogeneic immunogenicity 
(Figure 15). Before P8, when M2 were incubated with naive BALB/c MNC, they 
could not elicit primary allogeneic immune response, but inhibited the normal 
proliferation of allogeneic naive immune cells. After P10, the allo-immunogenicity of 
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mMSC was manifested, whereas there was no significant difference in the 
proliferation of allogeneic MNC stimulated by MSC at different passage numbers. 
The inhibitory effect on allogeneic MNC proliferation exerted by MSC at P5 and P7 
was significantly different from the stimulation of allogeneic MNC proliferation by 
MSC after P10 (p<0.05). 
 
 
4.2.3 Immuno-inhibition decreased along extended culture 
 
By incubating with proliferating allogeneic MNC which had been stimulated by 
allogeneic antigens (Figure 16A) and ConA (Figure 16B), immuno-inhibitory effect 
of MSC was retained and displayed consistent alteration at various time points during 
serial passage. The inhibitory effect decreased with increasing passage numbers of 
MSC. After P10, the decrease in the inhibitory effect exerted by MSC on allogeneic 
MNC proliferation was significant (p<0.05), particularly at P14 (p< 0.01).  
To confirm that the low inhibitory effect of MNC proliferation at P14 was effected by 
MSC, various titers of MSC at P14 were added into the proliferating MNC culture, 
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which were elicited by allogeneic antigens (Figure 16C) and ConA (Figure 16D). 
Both inhibitory effects displayed dose-dependent characteristics and were significant 
when the cell number increased to 5×104 (p<0.05 and p<0.01). 
 
 
4.2.4 Cytokines played a major role in the immuno-inhibition of MSC 
 
As the above results showed that MSC at P14 were immunogenic and retained weaker 
immuno-inhibitory properties than MSC at early passage numbers, as well as there 
was no increase of surface allo-MHC expression on them, it was suspected that less 
anti-inflammatory cytokines was secreted by P14 MSC. To address this question, the 
cytokine effect of P14 MSC was investigated. When the cell number ratio of MSC to 
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MNC was fixed at 1:10, MSC at P14 significantly inhibited the proliferation of MNC 
when stimulated with allogeneic antigens in both the presence and absence of direct 
contact (p<0.05 or p<0.01, Figure 17A), when compared to the positive control 
without MSC. Furthermore, the inhibitory effect of transwell-containing MSC was 
significantly stronger than 
a direct co-culture of 
MSC with BALB/c MNC 
and inactivated C57BL/6 
MNC (MLC) (p<0.01, 
Figure 17A). It was 
consistently observed that 
when the volume of MSC 
conditioned supernatant 
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was above 80μl, the inhibitory effect of supernatant was significantly stronger than 
that by direct contact (p<0.01, Figure 17B). There were similar inhibitory effect on 
MNC proliferation by P8 and P14 MSC (Figure 18). 
 
 
4.2.4.1 TGF-β and IL-10 were produced by different cell components in the 
co-culture of MSC and immune MNC 
 
Since soluble molecules play an important role in the immuno-inhibition of MSC and 
our previous report has demonstrated the involvement of TGF-β and IL-10, the effects 
of these two immuno-modulatory factors were intensively examined. When MSC at 
P14 were cultured alone, the cells secreted high levels of TGF-β (Figure 19A) and 
little IL-10 (Figure 19B). However, when MSC were co-cultured with BALB/c MNC 
and inactivated C57BL/6 MNC (MLC), the secretion of TGF-β within the supernatant 
increased significantly, regardless of whether MSC were separated from or in direct 
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contact with MNC (p<0.05, Figure 19A). By contrast, IL-10 secretion significantly 
increased only when MSC were separated from MNC by transwell inserts (p<0.05, 
Figure 19B). There was no significant difference in the secreted levels of TGF-β 
within the co-culture supernatant between direct contact and transwell separation.  
When MSC were added into MLC, it was found that both MSC and MNC synthesized 
TGF-β (Figure 20A), while only allogeneic responding lymphocytes synthesized 
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IL-10 (Figure 20B). After the addition of MSC, the synthesis of TGF-β by BALB/c 
responding CD4 and CD8 lymphocytes significantly increased (Figure 20C), while 
IL-10 levels did not exhibit a significant change (Figure 20D). 
 
4.2.4.2 TGF-β and IL-10 played a role in the immuno-inhibition of MSC 
 
When TGF-β blocking mAb was added into the co-culture of MSC and MLC, the 
MNC proliferation did not increase no matter whether MSC and MNC were directly 
contacted (Figure 21A-i) or separated by transwell (Figure 21A-iii). When the TGF-β 
blocking mAb was added into the MSC-containing transwell above MNC, MNC 
proliferated significantly (p<0.05). There was no significant increase of MNC 
proliferation when single anti-IL-10 blocking mAb was used (data not shown). 
However, in the presence of 10 μg/ml of TGF-β blocking mAb in the MNC-MSC 
direct-contact co-culture, the MNC proliferation increased significantly with the 
addition of 10 μg/ml IL-10 blocking mAb compared to the addition of 0.1μg/ml IL-10 
blocking mAb (Figure 21A-ii). Significant increase in MNC proliferation was 
observed when IL-10 blocking mAb was added into the MSC-containing transwell 
which was placed above MNC (p<0.05), but the proliferation was similar to that 
added with single TGF-β blocking mAb. These data suggest that TGF-β and IL-10 
may have a synergetic effect on the inhibition of MNC proliferation by MSC. And 
TGF-β may be an autocrine factor of MSC which could promote MSC to secrete more 
anti-inflammatory factors. 
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In order to know whether TGF-β and IL-10 take part in the immuno-inhibition of 
MSC, the concentrations of pro-inflammatory cytokines in different culture conditions 
of MSC after TGF-β and IL-10 blocking were firstly investigated. The selected 
pro-inflammatory cytokines for testing include IFN-γ (which mediates Th1 responses), 
IL-4 and IL-13 (which mediate Th2 responses), IL-3 (which stimulates T lymphocyte 
proliferation), IL-17 (which relates to many autoimmune diseases and allograft 
rejection), as well as IL-6 (which is an important mediator of acute phrase response). 
By multiplex assay of culture supernatant, there was no secretion of IL-3, IL-4 and 
IL-17 in the co-culture of MNC with MSC. However, there were low levels of IFN-γ 
(Figure 21B-i), and IL-13 (Figure 21B-iii), while moderate levels of IL-6 (Figure 
21B-ii) was detected. After the addition of TGF-β blocking mAb with/without the 
assistance of IL-10 blocking mAb, both the levels of IFN-γ and IL-13 increased 
significantly (p<0.05 or p<0.01, Figure 21B-i and iii). Additionally, a significant 
increase in IL-6 secretion was found only when both blocking antibodies were applied 
(p<0.05, Figure 21B-ii). 
 
 
4.2.4.3 The amount of TGF-β secretion did not decrease with extended culture of 
MSC 
 
As widely reported (Mazzieri, 2000; Nakao, 1997; Bellone, 1995; Amatayakul- 
Chantler, 1994), Mv1Lu is used specially for TGF-beta bioassay. The bioassay results 
demonstrated that proliferation of Mv1Lu without the addition of MSC supernatant 
 - 97 -
RESULTS                                                                              H.LIU 
was significantly higher than with the supernatant of MSC at both P8 and P14 (p<0.01, 
Figure 22A). There was no significant difference in the inhibitory effect exerted by 
the supernatant of MSC at P8 and P14 (Figure 22A). When the supernatant was 
obtained from the co-culture of MSC and MLC, the inhibition of Mv1Lu proliferation 
was significantly enhanced (p<0.01, Figure 22B). Also, the inhibitory intensity was 




In summary, the expression of MHC molecules on MSC did not upregulate with the 
increase in passage numbers, but the allo-immunogenicity of MSC gradually appeared 
after 5-day culture with allogeneic MNC. With the rise of the immunogenicity, the 
inhibitory effect of MSC on proliferating MNC diminished with the increase of 
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passage numbers. In the immuno-inhibitory effect of MSC, soluble molecules played 
an important role. These soluble immuno-inhibitory factors, two of which being 
TGF-β and IL-10, could be produced by different cell components in the co-culture of 
MSC and MNC. The production of TGF-β by MSC did not decrease with increased 
passage numbers.  
 
 
4.3 THE IMMUNE PROPERTIES OF MSC ALTERED IN IN VIVO APPLICATION 
 
Although alterations in immune properties of MSC displayed a trend with serial 
passage in vitro, their immune properties in vivo remained to be verified. To make a 
simple comparison of MSC between early passage numbers and late passage numbers, 
MSC at P8 and P14 were selected as representative populations. This is because 
mMSC at P8 is highly immuno-inhibitory and less immunogenic, whereas mMSC at 
P14 is highly immunogenic and less immuno-inhibitory.   
 
4.3.1 Significant MHC-I expression was detected on MSC grafts 
 
Although MSC kept very low surface expressions of MHC-I molecules along 
extended in vitro culture (Figure 14A), they would synthesize enough amount of 
MHC-I 12 days after allogeneic implantation, which could be detected as a tracking 
marker of MSC grafts using FITC conjugated primary MHC-I mAb (Figure 14B).  
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4.3.2 MSC at both early and late passage numbers displayed similar 
immunogenicity 
 
When BALB/c mice were primed with C57BL/6 MNC (positive control), their 
footpads swelled significantly 24 hours after challenge compared to those without 
priming (negative control, p<0.01, Figure 23A). When BALB/c mice were 
subcutaneously primed with MSC at P8 and P14, the footpad swelling was 
significantly stronger than the negative control (p<0.05), but significantly less than 
the positive control (p<0.05, Figure 23A). There was no significant difference 
between the footpad swellings primed by MSC at P8 and P14. These results were 
consistent with the local lymphocyte infiltration of mouse footpads collected from 
each group 48 hours after challenge (Figure 23B). There were much denser area of the 
inflammatory cell infiltration in the positive control footpads (Figure 23 Bi) and much 
smaller area of the inflammatory cell infiltration in the negative control footpads 
(Figure 23 Bii). However, the inflammatory cell infiltration in MSC groups were 
disperse (Figure 23Biii and iv). The footpad swelling was sustained for up to 48 hours 
after challenge (Table 3). 
 
4.3.3 MSC at an early passage number displayed immuno-inhibition by exposing to 
engraftment milieu  
 
In vitro, P8 and P14 MSC showed different immunological responses. However, both 
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of them could stimulate similar magnitudes of immune responses as shown in Figure 
23. Therefore, it is comparable of them for the testing in Figure 24. When MSC at P8 
and P14 were injected subcutaneously into the abdominal wall of the mice which 
were primed with the same MSC 10 days ago, the footpad swelling of BALB/c 
primed with MSC at P8 24 hours after challenged was significantly inhibited (p<0.05, 
Figure 24A), but not when injected with MSC at P14. The footpad swelling at 48 
hours after challenge was similar to that observed at 24 hours after challenge (Table 3). 
These results were consistent with the local lymphocyte infiltration results of mouse 
footpads collected from each group 48 hours after challenge (Figure 24B). There were 
much smaller and sparse area of the inflammatory cell infiltration in the footpad 
section of mice injected with P8 MSC (Figure 24 Bii) than P14 MSC (Figure 24 Biv) 
for challenge. 
 
4.3.4 MSC at a late passage number displayed immuno-inhibition by encapsulation 
 
To further investigate whether the immuno-inhibitory effect of MSC at P14 could be 
recovered in vivo by their secretion, MSC at P14 were placed in diffusion chambers 
and were implanted subcutaneously at challenge. Although the footpad swelling 
primed by MSC at P14 could not be inhibited by directly injecting the same cells at 
challenge, it was significantly inhibited by these chamber-encapsulated MSC 24 hours 
after challenge (p<0.05, Figure 25). The footpad swelling data 48 hours after 
challenge displayed a similar pattern to the above findings (Table 3). 
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4.3.5 Immuno-inhibition of encapsulated MSC at a late passage number could not be 
reversed by blocking TGF-β and IL-10 
 
To further investigate whether TGF-β and IL-10 played a dominant role in the 
inhibitory effect of mMSC on recalled immune responses, TGF-β and IL-10 blocking 
antibodies were premixed with mMSC before being injected into diffusion chambers. 
The efficacy of TGF-β blocking was verified as multiplex assays detected extremely 
low levels of TGF-β in the sera of BALB/c mice administered with blocking 
antibodies for 48 hours (Figure 27B). However, no IL-10 was detected in the sera of 
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all groups. To determine the effects of TGF-β blocking on MSC-induced delayed-type  
hypersensitivity, BALB/c mice were primed with C57BL/6 MNC and challenged with 
MSC at P14. Twenty four hours after challenge, there was an increase in footpad 
swelling but were not significantly rescued by MSC challenge regardless of whether 
cells were exposed to either anti-TGF-β antibody alone or with both anti-TGF-β or 
anti-IL-10 antibodies (p<0.05, Figure 26). There was also no significant difference in 





4.3.6 Immune related cytokines in serum were affected by the engraftment of MSC 
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at different passage numbers  
 
By multiplex assay of the sera harvested 48 hours after challenge, the amounts of 
TGF-β, IL-13, IL-17 and IL-6 displayed significant alterations in some experimental 
groups. When BALB/c mice were primed with MSC, the amounts of TGF-β, IL-13 
and IL-17 in sera decreased. The amount of TGF-β significantly decreased in the sera 
of mice primed with MSC at P14 (p<0.05, Figure 27A), while IL-13 and IL-17 levels 
exhibited a significant reduction in mice with MSC at P8 (p<0.05, Figure 27A).  
When BALB/c mice were primed and challenged with MSC, IL-6 exhibited a 
significant increase in the group with two direct implantation of MSC at P8 (p<0.05, 
Figure 28A). Although the amount of IL-6 did not increase in the sera of mice with 
two direct implantation of MSC at P14, it was significantly increased in the sera when 
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MSC at P14 were encapsulated in diffusion chambers and implanted at challenge 
(approximate 6-fold increase, p<0.01, Figure 28B). Upon further blocking of TGF-β 
in the chamber encapsulation of MSC at P14, the amount of IL-6 was lower than that 
without TGF-β blocking, but still much higher than controls (approximate 2-2.5 fold 
increase, p<0.01, Figure 28C). The amounts of IL-13 and IL-17 did not change 
significantly in the sera of mice primed and challenged with MSC (data not shown). 
Other pro-inflammatory cytokines, such as IL-3 and IL-4, was not detectable in the 
sera of all groups (data not shown). 
 
4.3.7 CD4+ and CD8+ lymphocytes in spleens and blood were affected by the 
engraftment of MSC at both early and late passage numbers 
 
To investigate the immuno-inhibitory effects of MSC in vivo, the lymphocyte 
composition in blood and spleen 48 hours after challenge were analyzed. There were 
significantly lower percentages of CD4+ and CD8+ cells in the splenic MNC 
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population but significantly higher percentages of CD4+ and CD8+ cells in blood 
MNC of BALB/c mice injected with P8 MSC and P14 MSC at priming, when 
compared to the controls (p<0.05, Table 3, Figure 29). At the same time point, the 
footpads of these groups were significantly thicker than the negative control while 
significantly thinner than the group primed with allogeneic MNC (p<0.05, Table 3, 
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Figure 29). There were evident local lymphocytes infiltrations into the footpads of 
these two experimental groups when sections were stained with hematoxylin and 
eosin (Figure 23B-iii and iv).  
When MSC at P8 were injected during footpad challenge, the percentages of CD4+ 
and CD8+ cells in splenic MNC further decreased compared to the controls (p<0.01, 
Table 3, Figure 29), whereas it was not changed in blood. At the same time, the 
footpad thickness of this group was not significantly increased over that of the 
negative control. Little lymphocytes infiltration was detected at the footpads injected 
with allogenic MNC (Figure 24B-ii). Although there was no significant change in the 
percentages of CD4+ and CD8+ cells in splenic MNC of BALB/c mice injected with 
MSC at P14 upon challenge, the percentages of CD4+ and CD8+ cells in blood MNC 
significantly increased (p<0.05, Table 3, Figure 29). Furthermore, there were evident 
local lymphocytes infiltrations at the footpads when injected with allogenic MNC 
(Figure 24B-iv).  
After further analysis of the CD4+ and CD8+ lymphocyte subtypes respectively, it was 
found that the ratio of CD4+ to CD8+ cells in splenic MNC of the BALB/c mice group 
which was primed and challenged by allogeneic MNC decreased significantly (p<0.05, 
Table 3, Figure 29), though no obvious change in the total percentages of CD4+ and 
CD8+ cells. However, when BALB/c mice were primed by MSC at both P8 and P14, 
both the percentages of CD4+ or CD8+ cells in splenic MNC significantly decreased 
(p<0.05, Table 3, Figure 29) despite maintaining a constant ratio, while their ratio in 
blood increased significantly (p<0.05, Table 3, Figure 29) without changing the 
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individual percentages. When BALB/c were injected with MSC at P8 upon challenge, 
both the percentages of CD4+ or CD8+ cells in spleen MNC were further decreased 
(p<0.01, Table 3, Figure 29) without changing their ratio, nor their ratio in blood. 
When BALB/c mice were injected with MSC at P14 upon challenge, only the 
percentage of CD8+ cells in spleen MNC was lower than the negative control (p<0.05, 
Table 3, Figure 29) while there was no change in other categories. When MSC at P14 
were contained in chambers and implanted subcutaneously at challenge, there was no 




In summary, in vivo data generally showed similar results to in vitro experiments with 
regards to the alteration of immune properties of MSC with increasing passage 
numbers, despite the presence of some minor variations. Furthermore, in vivo data 
provided insights to the immuno-inhibitory mechanisms of MSC.  
Although the expression of MHC-I molecule on MSC was mild in vitro and decreased 
with extended culture, its expression was distinct and steady for up to 12 days after 
the engraftment of MSC. The magnitudes of allogeneic immune responses elicited by 
MSC after 12 days of stimulation appears to be independent of passage numbers 
however, this immune response was limited in comparison to spleen MNC. When 
MSC were implanted and exposed to grafting environment, only MSC at an early 
passage number could exert a significant inhibitory effect on the secondary immune 
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response or the generation of immune memory. However, when MSC at a late passage 
number was separated from grafting environment by diffusion chambers, its 
inhibitory effect on the secondary immune response could be rescued. This inhibitory 
effect was not abolished by effective blocking of TGF-β and IL-10 in the diffusion 
chambers. 
Upon further analysis of the cytokines in the sera of all BALB/c recipients 48 hours 
after challenge, it was found that IL-3, IL-4 and IL-10 could not be detected in any of 
the groups. The decrease in TGF-β, IL-13 and IL-17 levels was only found in the sera 
of BALB/c mice when MSC were implanted once during priming, while an increase 
in sera IL-6 levels was constantly observed in groups where MSC exerted an effective 
inhibition on the secondary immune responses, in cases such as during the 
implantation of MSC at an early passage number with MNC challenge, the 
implantation of chamber-encapsulated MSC at a late passage number with MNC 
challenge, as well as the implantation of chamber-encapsulated MSC at a late passage 
number and blocking antibodies with MNC challenge. However, the amount of IL-6 
decreased after TGF-β was blocked. 
Upon further analysis of the lymphocytes in spleens and blood of all BALB/c 
recipients 48 hours after challenge, it was revealed that only limited numbers of 
lymphocytes migrated into the MNC challenged footpads after 12 days of priming 
with MSC. Lymphocytes were mostly retained in the peripheral circulation, and the 
draining of splenic lymphocytes was not replenished. By co-implantation of MSC at 
an early passage number with MNC challenge, the migration of lymphocytes to both 
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the MNC challenged footpads and peripheral circulation was impeded, and the 
proportion of splenic lymphocytes was further reduced. However, by co-implantation 
of MSC at a late passage number with MNC challenge, the migration of lymphocytes 
from spleen to blood and peripheral MNC challenge tissues was similar to that 
without co-implantation. Nonetheless, when these MSC at a late passage number were 
enclosed in diffusion chambers, the co-implantation of MSC would prevent the 
lymphocytes from migrating to the peripheral circulation and MNC challenge sites as 
well. 
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5.0 DISCUSSION 
 
5.1 THE DERIVATION, EXPANSION AND CHARACTERIZATION OF MSC 
 
Our attempt to isolate a sub-population of MSC was carried out in the mouse, as it is 
an important mammalian model for evaluating pre-clinical efficacy. 
 
5.1.1 The derivation and expansion of MSC 
 
To date, several publications have reported a variety of different methods for isolating 
and expanding mMSC, including the use of different isolation and expansion media 
containing serum from different species [Peister 2004], varying seeding densities and 
various enzymes for detachment [Meirelles Lda 2003], suspension culture [Shiota 
2007], seeding on fibronectin substratum [Tropel 2004, Breyer 2006] as well as the 
use of culture media containing different growth factor combinations [Jiang  2002, 
Sun 2003, Baddoo 2003, Tropel 2004, Breyer 2006]. In enriching mMSC from bone 
marrow, the greatest technical challenge is the removal of hematopoietic cells, in 
particular monocytes and macrophages. Previously, it was reported that bone marrow 
monocytes and macrophages play an important role in the proliferation and 
differentiation of hematopoietic cells in vitro [Mori 1990]. Besides a shortened 
trypsinization time, this study utilized silica to achieve a purer population of mMSC. 
Distinguished from previous published methods, the principle of using dense silica 
 - 113 -
DISCUSSION                                                                           H.LIU 
particles here is the rapid silica uptake by cultured macrophages which consequently 
causes cellular apoptosis upon internalization [Gilberti 2008]. Additionally, the 
silica-loaded cells can be separated from the rest of the cell population by 
Ficoll-hypaque fractionation. Results showed an abrupt decrease of CD11b+ cells after 
silica depletion. Following a subsequent negative selection, a highly purified 
population of CD11b-CD45-CD117-lineage- bone marrow cells with 99% purity can 
be attained as early as P5. 
In the same set of experiments, we also attempted to isolate a mMSC subpopulation 
with high proliferative capacity in vitro. From previous studies, mMSC exhibited a 
limited duration of survival ex vivo [Nadri 2007], and their survival was dependent 
upon supplementation of the culture medium with appropriate combination of growth 
factors [Jiang 2002, Tropel 2004, Fehrer 2006]. In our protocol, M2 could proliferate 
for more than 70 passages without the need for any growth factor supplementation 
and kept a consistent growth rate to achieve confluence within 3-4 days at a seeding 
density of 5×103/cm2. However, there may be a caveat to this as spontaneous 
transformation of mMSC had been observed in cultures by other groups. Zhou et al. 
reported increased chromosome number and multiple Robertsonian translocations at 
P3 that were coincident with the loss of contact inhibition [Zhou 2006], while Miura 
et al. observed mMSC transformation around P15 [Miura 2006]. In our study, we also 
observed aneuploidy and polyploidy in M2, but these were at low frequency in cells 
up to P35. At the same time, contact inhibition was maintained. 
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5.1.2 The characterization of MSC 
 
In this study, M1, M2 and M4 were plastic-adherent and could be successfully 
differentiated into osteogenic, chondrogenic, and adipogenic lineages. By fulfilling 
these criteria [Dominici 2006], all of them can thus be defined as MSC. However, M2 
was much more efficient in osteogenesis and chondrogenesis compared to M4 in vitro 
as supported by both qualitative and quantitative study data. Furthermore, high 
efficiency of osteogenesis and chondrogenesis was maintained even to late passage 
(P32) of M2. Moreover, ALP, OPN and OC synthesis could readily be detected in M2 
grafts as early as 12 days post-implantation even by ectopic subcutaneous injection. 
Although M1 showed high osteogenic potential in vitro, most of them were lost after 
12 days of implantation, and those remaining cell grafts synthesized little osteogenic 
matrix proteins. This implies that the M2 cell population is easily localized and has 
great potential to differentiate into the osteogenic lineage. It is well-known that OC is 
expressed only at the terminal stage of osteogenesis, playing a role in bone 
mineralization [Young 2003, Marie 2008]. By Alizarin red staining, small areas of 
mineral deposition had been detected in M2 graft. This further suggests that M2 might 
undergo mineralization as early as 12 days after engraftment. Thus, the properties of 
better localization and enhanced osteogenic potential would make M2 a better 
candidate in cellular therapy of bone diseases. 
In this study, a key difference was that M2 was derived after 1 hour incubation with 
silica, whereas M4 was derived after 4.5 hours incubation with silica. This suggests 
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that the bone marrow subpopulation with the greatest osteogenic potential had the 
tendency to engulf silica particles between 1 to 4.5 hours incubation. Another 
implication is that within a heterogeneous bone marrow population, cells with high 
capacity for osteogenesis might proliferate much faster than cells with high capacity 
for adipogenesis. Recent studies reported that the osteogenic differentiation of MSC 
could be enhanced by internalization of silica nanoparticles and that the survival of 
MSC was not adversely affected by the internalization [Huang 2008, Lipski 2008]. 
Nevertheless, this observed stimulation of osteogenesis was limited. It is unknown 
whether the silica utilized in this study had any influence on the osteogenic 
differentiation of M2. During the tri-lineage differentiation, we observed that CD73 
expression by M2 was maintained to the terminal stage of osteogenesis. CD73 was 
also expressed by osteogenic progenitors of M4 but not by undifferentiated M4 and its 
differentiated adipocytes. This would imply that CD73 expression might be a 
candidate marker for osteogenesis by mMSC. Indeed, this phenomenon was also 
similarly observed in human and rat MSC [Gharibi 2008, Siddappa 2008]. 
Based on our data, it was obvious that none of the tested surface molecules is a 
specific marker of mMSC, since tri-lineage differentiation was observed with mMSC 
populations deficient in some of these surface molecules. Furthermore, each 
population had different capacity of tri-lineage differentiation. Nevertheless, the 
results still imply that MSC expressing the combination of a number of these 
molecules might have higher capacity to differentiate into certain lineages. Thus, M2 
may provide a good model system for characterizing MSC subpopulations that are 
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most suited for bone regeneration and tissue engineering and also aid in the discovery 
of new surface markers. After implantation, mineral accumulation was detected in a 
few parts of M2 graft areas compared to the other areas. This result further certifies 
the fact that MSC are a heterogeneous cell population which contains cells at different 
developmental stages. The graft cells prior to mineralization may represent a group of 
cells which are more rapid in terms of their final bone formation. Therefore, M2 may 
also provide a good model system to identify bona fide MSC and osteogenic 
progenitors. Although silica can be used effectively to remove macrophages and 
monocytes, it is still necessary to use negative selection to deplete the remaining 
contaminating cells. Further optimization of silica particle size and incubation time 
for mMSC isolation may improve the efficiency of removing the unwanted 
hematopoietic subpopulation. 
 
5.1.3 MSC as a candidate for immunological testing 
 
Due to the quality of MSC being dependent on the age and health status of the donor, 
autologous MSC may not be optimal for the treatment of aged patients [Quarto 1995, 
Muschler 2001]. Thus, it is important to identify a subpopulation of MSC suitable for 
allogeneic transplantation and with high proliferative capacity as in vitro expansion is 
inevitable to obtain sufficient numbers of MSC for therapeutic purpose. As previously 
reviewed, the biology of MSC would change in ex vivo culture. However evidence on 
the alteration of their immuno-biology along extended culture is lacking. Therefore, 
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the major aim of this study was to thoroughly evaluate the immuno-properties of 
MSC with increasing passage numbers. 
Based on above data, all three bone marrow stromal cell populations displayed 
general MSC characteristics, including plastic-adherence, tri-lineage differentiation 
potential, stable expression of a certain MSC molecule combination, and with little 
hematopoietic cell contamination. Particularly, M2 showed higher osteo- and 
chondro- differentiation potential and lower adipogenic potential, which may serve as 
a better cell source in regenerative application for bone and cartilage than M1 and M4. 
A prolonged survival and high proliferative capacity of M2 in vitro, while maintaining 
normal karyotype, offer the ease of generating abundant cells at each passage number 
for different testing. Furthermore, M2 demonstrated normal biological functions in 
vivo, such as bone matrix protein synthesis and secretion, as well as a steady residence 
at subcutaneous injection sites up to 12 days post-implantation, providing a good tool 
for observing local reaction around grafts. Therefore, M2 were the ideal MSC 
subpopulation for further allogeneic immunological studies. 
 
5.2 THE IMMUNOGENICITY OF MSC WITH INCREASING PASSAGE 
NUMBERS 
 
5.2.1 Inconsistent immunogenic results of MSC in vitro and in vivo 
 
From our results, MSC displayed immuno-privileged properties at P5. However, on 
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further analysis, the immuno-stimulatory effect was manifested after P10; whereas the 
expression of MHC-I and –II molecules did not change along with serial passage. 
This would imply that the observed alteration in immunogenicity was not primarily 
dependent on MHC molecules and that the immune rejection of MSC could not be 
predicted by changes in the expression of classical MHC molecules in vitro. Indeed, 
the same phenomenon had also been observed with rabbit MSC [Liu 2006]. However, 
the expression of MHC molecules on rabbit MSC was induced/enhanced after 
implantation [Liu 2006] and similar was observed with mouse MSC. As a 
consequence, in mice, leukocytes infiltration was observed at site of allogeneic MSC 
graft and footpad swelling (or the secondary immune responses) was triggered by the 
challenge of MNC carrying the same allogeneic MHC as priming MSC.  
MSC that were little immunogenic (MSC at P8) or evidently immunogenic (MSC at 
P14) after 5 days of testing in vitro, provoked similar magnitudes of footpad swelling 
in vivo when primed into BALB/c mice. The observed rapid secondary immune 
reaction implies that the in vitro results on the immunogenicity of MSC are not 
directly predictive of their long-term in vivo action. The difference between the in 
vitro and in vivo results could be attributed to the varying time durations required by 
MSC at different passage numbers to upregulate alloreactive molecules. For MSC at 
an early passage number, they may require more than 5 days in vitro to express 
similar amount of allogeneic antigens as MSC at a late passage number. The in vivo 
priming period of 10 days might have provided time for them to do so. Otherwise, the 
complex microenvironment of engraftment might have expedited the expression of 
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allogeneic antigens on MSC. 
Nevertheless, the survival of MSC grafts 12 days after subcutaneous injection in 
BALB/c mice suggests that these cells might display additional mechanisms to protect 
themselves from allogeneic immune cells. This protective effect could not be detected 
in vitro during mixed lymphocyte culture. On day 12 post-implantation, MSC grafts 
were matrix-embedded, with high deposition of OPN and OC. There is a possibility 
that bone-associated extracellular matrix produced rapidly after implantation might 
hinder physical interaction between the implanted allogeneic MSC and host immune 
cells, thereby conferring a protective effect. Indeed, lesser leukocytes infiltration was 
found in the matrix-rich area of MSC graft. Another assumption is that MSC has both 
inhibitory and stimulatory effects on the growth of immune cells. This balance might 
skew towards stimulation with serial passage in vitro, while it might otherwise skew 
towards inhibition upon encountering certain factors in vivo. A third possibility is the 
selective ability of MSC grafts to support activity of those regulatory hematopoietic 
cells by means of cell-to-cell contact or secreted cytokines. 
 
5.2.2 The relationship of immune cytokines with the immunogenicity of MSC 
 
By multiplex assay on sera of BALB/c mice primed with MSC, the amounts of IL-13, 
IL-17 and TGF-β decreased. In particular, the amount of TGF-β reduced significantly 
when MSC at P14 were used for priming, while levels of IL-13 and IL-17 decreased 
significantly when MSC at P8 were used for priming. These data suggest that the 
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mechanisms in the generation of allogeneic immune responses by MSC at various 
passage numbers may be complex. Besides the activation of Th1 cells and cytotoxic T 
cells during allogeneic immune responses, MSC may also inhibit the activation of 
immune cells secreting IL-13, IL-17 and TGF-β. Furthermore, MSC at a late passage 
number may exert a profound inhibitory effect on TGF-β-secreting cells, while MSC 
at an early passage number may have a potent inhibitory effect on IL-13 and IL-17 
producing cells. TGF-β has been reported as a major cytokine secreted by CD25+ 
regulatory T cells with the ability to block the activation of lymphocytes and 
monocyte-derived phagocytes [Shevach 2009]. Therefore, one possible way of MSC 
to elicit immune response may be achieved through the down-regulation of Treg cells. 
IL-13, secreted mainly by Th2 cells, is an important regulator in Th2 cell development 
and mediator of allergic inflammation [Wynn 2003]. Hence, its down-regulation in the 
sera of BALB/c mice primed with MSC suggests the ability of MSC to impair in vivo 
Th2 polarization while strengthening Th1 immune response. IL-17 is now believed to 
be the dominant cytokine secreted by T helper 17 (Th17) cells, which has a 
developmental pathway distinct from Th1 and Th2 cells. It is a pro-inflammatory 
cytokine that exacerbates ongoing inflammation [Maione 2009] and is involved in 
many immune-related diseases, such as rheumatoid arthritis, asthma, lupus, allograft 
rejection and anti-tumour immunity [Aggarwal 2002]. Reports have suggested a 
dichotomy in the generation of Th17 cells and Treg. In the presence of 
pro-inflammatory cytokines (such as IL-6), TGF-β could induce in vitro 
differentiation of naive T cells into IL-17-producing cells [Basso 2009] or convert 
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Treg to Th17 cells [Mitchell 2009]. This could account for the reduced levels of IL-17 
detected in the sera of MSC primed BALB/c mice when there is a lower amount of 
TGF-β despite a normal IL-6 level. Hence, inhibition of the pro-inflammatory 
cytokine, IL-17 could also contribute to the limited secondary immune response 
provoked by allogeneic MNC in the mice primed with MSC.  
 
5.2.3 The relationship of immune cells with the immunogenicity of MSC 
 
When BALB/c mice were primed with MSC, although their footpads accumulated 
more T lymphocytes upon challenge than those of mice without priming, the 
magnitude of lymphocyte infiltration was significantly lower than that of mice with 
allogeneic MNC priming. Interestingly, the percentage of T lymphocytes in blood 
MNC significantly increased, particularly CD4+ T cells, but not CD8+ T cells. 
Furthermore, the percentage of both CD4+ and CD8+ T-lymphocytes in splenic MNC 
was significantly decreased while maintaining the proportion of CD4+ T cells to CD8+ 
T cells. These results suggest a limited ability of MSC to induce a secondary immune 
response. Although both CD4+ and CD8+ cells are mobilized from the spleen into 
peripheral circulation, CD4+ T cells and to a lesser extent, CD8+ T cells are prevented 
from entering footpads and are retained in blood. These results further point to a 
defective memory immune response when primed by MSC. Meanwhile, it was found 
that the decreased proportions of CD4+ and CD8+ T cells in the recipients’ spleens 
primed by MSC could not recover as fast as those in the recipients’ spleens primed by 
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MNC. It indicates a limited or delayed proliferation of spleen lymphocytes during 
secondary immune response. Both CD4 and CD8 cells are equally affected. 
  
5.3 THE IMMUNO-INHIBITION OF MSC WITH INCREASING PASSAGE 
NUMBERS 
 
5.3.1 Immuno-inhibition of MSC on the primary and secondary immune responses 
 
With increasing passage numbers, the immuno-inhibitory effects on allogeneic MNC 
proliferation of MSC diminished in vitro, with statistically significant changes after 
P10. These alterations were consistent with the observed inhibition of footpad 
swellings by MSC at P8, but not by MSC at P14. However, there was a difference 
between the immune responses induced in vitro and in vivo. In the mixed lymphocyte 
culture, MSC were added into the system at the beginning of the primary immune 
response. However, in the footpad swelling testing, MSC were implanted at the 
beginning of both the primary and the secondary immune responses. Therefore, the in 
vitro results are more indicative of MSC’s inhibitory effects on the initiation of 
allogeneic primary immune response. Since MSC at different passage numbers 
showed similar magnitude of delayed-type immune response upon single priming, the 
difference of the footpad swelling inhibition by implanting MSC of different passage 
numbers at the time of allogeneic MNC challenge would be better to explain the 
inhibitory effect of MSC on the initiation of the recalled immune response, 
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particularly the effect seen within 2 days of challenge. For that reason, above results 
connote that the inhibitory ability of MSC on both primary and secondary immune 
responses will decrease along extended culture. The proliferation inhibition of 
recipients’ naive and memory lymphocytes may be one of the inhibitory mechanisms 
of MSC at an early passage number. 
Although a very weak immuno-inhibitory effect was observed when MSC at P14 
were co-cultured with MNC by direct contact, a significantly enhanced inhibition of 
allogeneic MNC proliferation could be achieved by separating MSC at P14 from 
MNC. Furthermore, the inhibition of footpad swelling could be rescued by 
encapsulation of MSC at P14 during challenge with subcutaneous implantation. These 
evidences implicated a major role of soluble mediators in the immuno-inhibitory 
effects of MSC on both the primary and secondary immune responses. Additionally, 
the secretion of immuno-inhibitory soluble mediators by MSC persisted to after the 
appearance of immuno-stimulatory surface molecules. Thus, in an extended period of 
time, these secretory molecules can counteract the immuno-stimulatory effect exerted 
by the immuno-stimulatory surface molecules of MSC, such as MHC-I.  
In contrast, MSC after P10 did not inhibit but stimulated the proliferation of naive 
allogeneic MNC when these cells were co-cultured without external stimulation. 
Although the inhibitory effect diminished with extended culture, MSC at all tested 
passage numbers retained an inhibitory effect on the proliferation of activated MNC, 
in both the presence and absence of direct cellular contact. These proliferating MNC 
could be activated by either mitogen or MHC-restricted antigens on allogeneic MNC. 
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These would suggest the inability of soluble mediators released by MSC at late 
passage numbers to completely inhibit the immune responses of naive MNC triggered 
by the immunogenic surface molecules of MSC. Pro-inflammatory molecules secreted 
by activated MNC might enhance the secretion of anti-inflammatory molecules by 
MSC. Otherwise, activated MNC could be more sensitive to apoptosis or anergy 
induced by MSC secretion of suppressive factors, as compared to naive MNC. 
Another possible explanation is that the nascent MNC arising from proliferation 
might be more unstable and easily skewed towards an anti-inflammatory phenotype 
when exposed to the immuno-inhibitory mediators secreted by MSC, as compared to 
natural naive MNC. 
 
5.3.2 The relationship of immune cytokines with the immuno-inhibitory properties 
of MSC 
 
Previously, it was similarly proposed that the immuno-suppression of MSC were 
enhanced by pro-inflammatory cytokines, such as IFN-γ [Liu 2006, Krampera 2006, 
English 2007]. In our investigations, we also detected low levels of pro-inflammatory 
molecules, such as IFN-γ, IL-6 and IL-13, in the co-culture supernatant in spite of the 
presence of immuno-suppression. In the presence of these pro-inflammatory cytokines, 
the amounts of both TGF-β and IL-10 in the same supernatant were higher than those 
in MSC monoculture supernatant, particularly TGF-β. It has been known that TGF-β 
blocks advancement through G1 phase of cell cycle by interference with cyclin 
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[Hanahan 2000]. This effect is consistent with the findings that MSC arrest T cells in 
the G0/G1 phase of the cell cycle [Jones 2007, Glennie 2005, Ramasamy 2007, Siegel 
2009]. These evidences indicate that the TGF-β secretion by MSC is possibly 
up-regulated by pro-inflammatory cytokines produced by activated MNC so as to 
enhance the immuno-inhibitory effect of MSC. This helps to explain the maintenance 
of immuno-inhibition of MSC at a late passage number on activated MNC but the loss 
of such effect on naive MNC.  
It was also previously proposed that MSC could induce either apoptosis [Augello 
2005, Plumas 2005] or anergy [Glennie 2005, Batten 2006] of activated T cells. 
Although it was reported that MSC could induce the production of regulatory CD4+ 
[Maccario 2005, Aggarwal 2005] and CD8+ T cells [Djouad 2003] as well as 
regulatory antigen-presenting cells [Zhang 2004, Aggarwal 2005, Beyth 2005], it is 
unclear whether the sensitivity of these induction is different between native naive 
MNC and nascent naive MNC from proliferation as deduced in part 5.3.1. 
Based on the above analysis, it can be inferred that soluble mediators play an 
important role in the inhibition of MNC proliferation, particularly after the lost of 
contact-mediated immuno-inhibition by MSC. Our previous study has reported the 
important of both TGF-β and IL-10 as immuno-modulatory cytokines in the 
immuno-inhibition of MSC [Liu 2006]. Here, we investigated their effects more 
rigorously. The results revealed that TGF-β could be secreted by both MSC and MNC, 
while IL-10 was only synthesized by MNC under the induction of MSC, particularly 
when MSC were separated from MNC in transwell co-cultures. This suggests that the 
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MSC secretion is able to induce the production of IL-10 by MNC, and the contact of 
MSC with MNC somehow reduces this ability. Compared with the secretion of TGF-β 
by MSC at P8, MSC at P14 secreted similar amounts during monoculture. When 
MSC at both passage numbers were co-cultured with MNC, similar amounts of active 
TGF-β were detected in their supernatant. These results suggest that the secretion of 
some innate immuno-modulatory molecules by MSC in vitro may not decrease with 
increasing passage numbers, and their abilities to induce MNC to produce 
immuno-modulatory molecules may be similar. This deduction is consistent with the 
above inference that the diminishment of immuno-inhibitory effects of MSC at 
increasing passage numbers is probably caused by the appearance of immunogenicity.  
In this study, we found that blocking TGF-β could significantly increase the levels of 
IFN-γ and IL-13 in co-culture supernatant. However, TGF-β had no significant effect 
on the inhibition of MSC effects on footpad swelling induced by double allogeneic 
MNC stimulations. This suggests that TGF-β may have some role in the 
immuno-inhibitory activity of MSC but is not the major inhibitory cytokine of MSC. 
Other inhibitory molecules could compensate for the deficiency of TGF-β-mediated 
inhibition. Even though it was also found that further blocking of IL-10 could increase 
the secretion of IL-6 in co-culture supernatant, it could not reverse the inhibition by 
MSC secretions on footpad swelling which was caused by double allogeneic MNC 
stimulations. Additionally, IL-10 could not be detected in serum, regardless of 
whether recipient mice were directly implanted with MSC or with diffusion chamber 
containing MSC. This implies a role of IL-10 in the local inhibitory effects of MSC 
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while its long-distance effect is limited.  
Among all tested cytokines, the most significant alteration observed in both 
supernatant and sera levels was IL-6. In all groups displaying significant inhibition of 
footpad swelling, the sera amount of IL-6 increased prominently, regardless of 
whether MSC were implanted at an early passage number or by diffusion chamber. It 
implies an important role of IL-6 in the immuno-inhibition of MSC. As only secreted 
cytokines is able to diffuse into peripheral circulation, it is postulated that IL-6 
probably acts in a paracrine or endocrine manner. These proposed mechanisms are 
actually not necessarily exclusive. It is previously explained that IL-6 is secreted by 
MSC [Haynesworth 1996, Majumdar 1998] and is involved in the 
immuno-suppression of MSC [Liu 2005, Djouad 2007, Toubai 2009] by preventing 
the development of bone marrow progenitors to DC and reversing the mature DC to 
an immature phenotype [Djouad 2007]. At the meantime, it also exerts 
immuno-suppressive effect on the production of TNF-alpha and IL-1, while activating 
the production of IL-1Ra and IL-10. These protective effects could be acting locally 
and at distal sites [Liu 2005]. Another finding in our study was a prominent increase 
of IL-6 level in the supernatant when MSC and MNC were cultured in contact and 
with the application of both TGF-β and IL-10 blocking antibodies. This data is 
consistent with previous report that TGF-β and IL-10 could inhibit the production of 
IL-6 in an additive manner in vitro [Chen 1996]. Although the inhibitory effect of 
IL-6 on DC maturation may be one of the immuno-suppressive mechanisms of MSC, 
experiments with neutralizing antibodies suggested that IL-6 probably does not play a 
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dominant role [Djouad 2007].  
Besides TGF-β, IL-10 and IL-6, some other cytokines, such as IL-3 [Batten 2006] and 
IL-4 [Denizot 1999, Glennie 2005], were reported to be involved in the inhibition of 
MSC. In both ex vivo and in vivo investigations, IL-3 and IL-4 were not detected in all 
tested supernatant and sera. This suggests that these two molecules hardly play any 
role in the immuno-inhibition of MSC. Because IL-4 are a major cytokine in the 
skewing naive T helper cells to Th2 cells, this result would imply that the propagation 
of Th2 polarization may not be a major mechanism for MSC to exert 
immuno-inhibitory effect. 
In our investigations, even though the chamber-constrained MSC were implanted 
some distance away from the site of MNC challenge, they could still exert inhibitory 
effects on the footpad swelling induced by allogeneic MNC. This would thus imply 
that MSC constitutive secretion of potent immuno-inhibitory molecules may play an 
inhibitory role in a paracrine or endocrine manner. In previous publications, 
prostaglandin E2, hepatocyte growth factor, indoleamine 2,3-dioxygenase and soluble 
HLA-G were reported to be involved in the immuno-inhibition of MSC and were 
present in blood circulation [Jones 2008]. They have potent inhibitory effects on T 
cell proliferation and natural killer cell function. However, whether these factors are 
the major immuno-modulatory mediators of MSC remains controversial [Tse 2003].  
 
5.3.3 The relationship of immune cells with the immuno-inhibitory property of 
MSC 
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Excluding the effect of non-specific immune cells, it was found that after 48 hours of 
challenge, the footpads of mice with allogeneic MNC priming accumulated much 
more T lymphocytes than those without priming. Furthermore, the proportion of 
splenic CD8+ T cells to CD4+ T cells increased significantly without changing the 
percentage of T lymphocytes in splenic and blood MNC. This suggests a preferential 
migration of activated splenic T cells to the challenge site and not being retained in 
blood. In this secondary immune response, splenic CD8+ T cells proliferate faster than 
CD4+ T cells. Also, the continuously proliferating cells could maintain the 
homeostasis of total T lymphocytes in spleen.  
By co-implanting MSC with allogeneic MNC during challenge, the tissue infiltration 
of T lymphocyte and the proportion of T lymphocyte in blood and splenic MNC in 
mice displayed variations with different passage numbers of MSC applied. When 
MSC at P8 were used, the T lymphocyte infiltration at the challenge site significantly 
decreased. At the same time, the tested parameters of blood T cells were close to those 
of negative control, while the percentage of T lymphocytes in splenic MNC and the 
respective percentages of splenic CD4+ and CD8+ T cells further decreased compared 
to those in the negative control. However, when MSC at P14 were used, the T 
lymphocyte infiltration at the challenge site did not decreased significantly. Also, the 
percentage of T cells in blood MNC and the respective proportion of CD4+ and CD8+ 
T cells in blood were kept higher than those of the negative control and similar to 
those without co-implanting MSC at P14. Meanwhile, the percentage of T 
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lymphocytes in splenic MNC was unchanged. These results imply that MSC at an 
early passage number can prevent the migration of T lymphocytes from the spleen to 
peripheral circulation and further inhibit the proliferation of splenic T cells in the 
recalled immune response, involving both CD4+ and CD8+ cells. These effects were 
strong by exposing to graft environment within 2 days post-implantation. 
Nevertheless, MSC at a late passage number lost these functions. 
However, the inhibitory effect on lymphocyte migration from spleen to peripheral 
circulation could be reversed by constraining MSC at a late passage number in 
diffusion chambers. When chamber-constraint MSC at P14 was co-implanted, all 
parameters of lymphocytes in spleens and blood were unchanged compared to 
negative control. Hence, this would suggest that the inhibition of lymphocyte 
migration is probably one of the major mechanisms by which MSC exerts its 
immuno-suppressive effect in vivo. This function is mainly cytokine mediated and 
could be maintained in MSC after prolonged culture. Although the mean percentage 
of splenic T cells was low when chamber-constraint MSC at P14 were co-implanted, 
it had no significant difference from the negative control due to a large standard error. 
Therefore, it could not be deduced whether the inhibition of splenic T cells 
proliferation in the recalled immune response is related to the contact of MSC at an 
early passage number with microenvironment or cytokine mediation. A larger sample 
size may be required to answer this question.  
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6.0 CONCLUSIONS AND RECOMMENDATIONS  
 
In conclusion, the alteration of MSC immunobiology with prolonged culture is their 
intrinsic property. By using the MSC subpopulation derived from C57BL/6 mice, we 
have found that the immunogenicity of MSC gradually enhanced with no 
up-regulation of MHC molecule expression along increasing passage numbers in vitro; 
while the immuno-inhibitory property, although being detected in all tested passage 
numbers, showed a decline with increasing passage numbers of MSC. The weak 
immuno-inhibitory effect of MSC at a late passage number can be greatly enhanced 
when MSC and immune cells were compartmentally segregated. This implicates a 
role of secretory factors in immuno-suppression by MSC. 
Regardless of passage number, MSC would induce immune memory after 10 days of 
engraftment. However, the elicited memory response was limited and involved 
mechanisms that were partially different from those of allogeneic MNC. One of the 
mechanisms might be due to the blockade of T lymphocytes, particularly CD4+ cells, 
from gaining entry to the peripheral tissues when challenge by MSC. Another 
mechanism could be the down-regulation of cytokines, such as TGF-β, IL-13 and 
IL-17. Within 2 days of implantation, MSC at an early passage number could exert 
potent inhibitory activity on memory response when exposed to the graft 
microenvironment. Besides the prevention of T lymphocytes migration to peripheral 
tissue, they also prevented these lymphocytes from exiting the spleen and inhibited 
the proliferation of spleen lymphocytes. However, this was not observed when MSC 
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at a late passage number were exposed to the graft microenvironment. Only when 
they were separated by diffusion chambers, similar magnitude of lymphocyte 
migration suppression as MSC at an early passage number was observed. 
Evidently, cytokines play very important roles in the immuno-inhibition of MSC. In 
particular, their effects become prominent when MSC are at late passage numbers and 
have lost their immuno-privileged property. While TGF-β and IL-10 were found to be 
involved in the immuno-inhibition of MSC in vitro, their effects were not significant 
in vivo. IL-6 was found to be elevated in sera whenever a significant inhibition of the 
memory immune response was observed. Furthermore, its level was regulated by 
TGF-β and IL-10. Among the tested cytokines, TGF-β and IL-6 were detected in sera, 
while IL-3, IL-4 and IL-10 were not. The former cytokines can be secreted by MSC, 
while the latter cytokines are dominantly secreted by MNC. Hence, TGF-β and IL-6 
may exert their immuno-regulatory effects in a paracrine or endocrine manner. 
Based on the above findings, we can see a strong relationship between in vitro 
expansion period of MSC and their resultant immune response. Clearly, implanting 
allogeneic MSC at different biological status would affect their efficacy and efficiency 
in therapy. Hence, the number of passages that MSC are subjected to prior to 
experimentation may be a confounding factor when applied to immunological studies. 
Since MSC in diffusion chamber play a more sustainable immuno-inhibitory effect 
than direct implantation, constructing a chamber-like device to contain MSC during 
clinical immunotherapy may improve its efficacy. Furthermore, promoting matrix 
embedding of MSC and their differentiated descendants would aid in achieving a 
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successful allogeneic engraftment for regenerative medicine.  
Although above findings have clearly proved the hypothesis that the immunobiology 
of MSC will alter with extended ex vivo culture and various mechanisms are involved, 
there are more questions raised. It is apparent that the immuno-inhibition of MSC is 
dependent on multiple cytokines. Up to now, only limited cytokine candidates have 
been studied and the dominant cytokines involved has yet to be identified. In addition, 
it is necessary to elucidate factors involved in the shifting of MSC from its 
immuno-privileged status to an immunogenic phenotype. Ability to maintain the 
epigenetics of MSC that confers its immune-privileged status would greatly aid 
regenerative medicine. In the TGF-beta blocking testing in vivo, the extra low 
TGF-beta level in serum might affect the normal biology of host mice exerted by 
TGF-beta. Therefore, it requires cautious explanation on the TGF-beta effect in this 
model. Although above findings have been tested in a mouse model, they might not be 
representative of what is happening in humans. Hence, the relationship between the 
immuno-biological differences of MSC at different passage numbers and the 
therapeutic results in different diseases and cases require further investigation. 
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